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The Anaphase Promoting Complex/Cyclosome (APC/C) regulates progression 
through mitosis by targeting important cell cycle regulators for ubiquitin-mediated 
proteolysis.  It consists of at least 13 different subunits; the function of many of 
which is unknown.  Recent work in the Turnell laboratory has suggested that 
protein levels of the APC/C subunit APC5 vary during mitosis.  APC5 has also 
been implicated in additional functions, aside from cell cycle regulation, in 
chromatin structure and transcriptional regulation.  The aim of this study was to 
understand further the roles of APC5 in APC/C regulation and its relationship with 
chromatin.  Here, I show that APC5 is degraded during mitosis in a spindle 
assembly checkpoint-independent manner.  However, I also determined that a 
small proportion of the APC5 protein remained during mitosis, indicating distinct 
pools are present within the cell, possibly performing different functions.  I found 
that APC5 binds to chromatin and Western blotting results suggest the presence 
of post-translationally modified APC5 associated with chromatin.  I used mass 
spectrometric analysis of proteins immunoprecipitated with APC5 from chromatin 
fractions to discover a number of novel binding partners, including proteins 
involved in chromatin modification/transcription regulation, mRNA processing and 





1.  INTRODUCTION ............................................................................................... 1 
1.1  Hypothesis and Aims ................................................................................... 11 
2.  MATERIALS AND METHODS ........................................................................ 12 
2.1  Cell Culture ................................................................................................. 12 
2.2  Cell Synchronisation .................................................................................... 12 
2.3  Plasmid Amplification and Purification ......................................................... 13 
2.4  Transfection ................................................................................................ 13 
2.5  Western Blotting .......................................................................................... 14 
2.6  RNA Preparation and RT-qPCR .................................................................. 15 
2.7  Chromatin Isolation ..................................................................................... 17 
2.8  Immunoprecipitation - Mass Spectrometry (IP-MS) ..................................... 18 
3.  RESULTS ........................................................................................................ 20 
3.1  APC5 Protein Levels are Reduced During Mitosis ...................................... 20 
3.2  Loss of APC5 Protein is not SAC-Sensitive ................................................ 21 
3.3  APC5 Protein Stability ................................................................................. 23 
3.4  FLAG-APC5 Protein Levels are Reduced in Mitosis ................................... 26 
3.5  Phosphorylation Status of APC5 in Mitosis ................................................. 30 
3.6  APC5 Binds to Chromatin ........................................................................... 33 
3.7  Function of APC5 in Chromatin ................................................................... 36 
4.  DISCUSSION .................................................................................................. 41 
5.  REFERENCES ................................................................................................ 48 
6.  APPENDIX – APC5 IP-MS Data ..................................................................... 52 
6.1  Nucleoplasm ............................................................................................... 52 
6.2  Chromatin + 0.25 M NaCl ............................................................................ 53 










1.  INTRODUCTION 
 
 
The cell cycle, or the process of cell division, consists of 5 stages: G0, G1, S, G2 
and M (Fig. 1).  DNA replication occurs during S phase and the cell undergoes 
mitosis and division during M phase.  G1 and G2 are the ‘gap’ phases of the cycle, 
when the cell responds to environmental signals and commits to the cell cycle 
(G1) and when the cell prepares for entry to mitosis (G2).  G0 is the ’resting’ 
phase, which occurs when the cell is quiescent.  Checkpoints exist at multiple 
points through the cycle, which sense aberrant or incomplete cell cycle events and 
signal to arrest the cycle, e.g. to ensure DNA is correctly replicated and repaired 
before the cell divides.  Progression through the cell cycle is driven by the cyclin-
dependent kinase (Cdk) family of serine/threonine kinases, along with their 
regulatory partners, cyclins.  Although the levels of Cdks are constant, the levels of 
different cyclins vary throughout the cell cycle, allowing the formation of distinct 
complexes at each stage to trigger different events and ensure sequential 

























Figure 1 – Diagram of the Cell Cycle 
The cell cycle is split into five stages: G0, G1, S, G2 and M, as shown.  A number 
of checkpoints are present to control cell cycle progression, including the 
restriction point (R) at the end of G1 after which the cell will irreversibly enter the 




Cell division needs to be tightly controlled to ensure each daughter cell inherits the 
correct number of chromosomes.  This involves limiting the presence of cell cycle 
regulators, including cyclins, to only when their functions are required, both by 
regulating their transcription and through protein degradation, which guarantees 
the cell cycle is irreversible and progresses in the correct order (Benanti, 2012).  
Cell cycle-mediated protein degradation mainly occurs via the ubiquitin-
proteasome pathway.  This pathway utilises a series of enzymes to promote 
ubiquitination.  Initially, the E1-activating enzyme catalyses activation of ubiquitin 
in an ATP-dependent step, before binding of ubiquitin to a cysteine in E1 via a 
thio-ester bond.  Ubiquitin is transferred to an E2 ubiquitin-conjugating enzyme 
and covalently linked via a cysteine in the active site.  The E2 enzyme then acts 
with an E3 ubiquitin ligase, to transfer the ubiquitin to a lysine residue in the target 
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protein.  This process can be repeated to give polyubiquitinated proteins that are 
then targeted by the 26S proteasome for degradation (Fig. 2) (Hershko and 
Ciechanover, 1998).  There is also evidence that multiple mono-ubiquitination can 
act as an alternative degradation signal, e.g. for cyclin B1 (Dimova et al., 2012).  
The E3 enzyme provides the substrate specificity in the reaction and thus, it is at 
this step that most regulation of the pathway occurs (Deshaies and Joazeiro, 
2009). 
Figure 2 – Ubiquitin-Proteasome Pathway 
Diagram illustrating the polyubiquitination process to target proteins for 
degradation.  Ubiquitin is first activated by an ubiquitin-activating enzyme, E1 (step 
1), before the activated ubiquitin is transferred to an ubiquitin conjugating enzyme, 
E2 (step 2).  In step 3, ubiquitin is attached to the target protein by an E3 ubiquitin 
ligase and repeated to give a polyubiquitinated substrate, before it is degraded by 
the 26S proteasome in step 4 (Corn, 2007). 
 
The anaphase promoting complex or cyclosome (APC/C) is an E3 ubiquitin ligase 
that targets many cell cycle regulators for degradation to control mitotic 
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progression and entry into S phase (Sudakin et al., 1995; Clijsters et al., 2013).  
The APC/C targets substrates for ubiquitin-mediated proteolysis in a temporally-
coordinated manner in order to promote cell cycle progression (Fig. 3).  Currently, 
the human APC/C is known to have at least 55 substrates, but the true figure is 
estimated to be more than 100 (Meyer and Rape, 2011).  It becomes activated 
upon Nuclear Envelope Breakdown (NEBD), when it targets cyclin A and Nek2A 
(den Elzen and Pines, 2001; Hames et al., 2001).  At metaphase, it directs the 
ubiquitination of Securin and cyclin B1 to enable metaphase-anaphase transition 
(Stemmann, 2001; Clute and Pines, 1999), before targeting Aurora kinases (as 
well as cyclin B1) to permit chromatid segregation and cytokinesis (Floyd et al., 
2008).  It remains active in G1 to maintain low levels of mitotic Cdk activity and 












Figure 3 – Temporal targeting of APC/C substrates (van Zon, 2010) 
Diagram illustrating the role of the APC/C in cell cycle progression, showing at 




The APC/C interacts with two different co-activators: Cdc20 from pro-metaphase 
to anaphase and Cdh1 from anaphase through G1 (Sudo et al., 2001).  Studies 
have shown that these proteins function both to activate the APC/C (Fang et al., 
1998) and to provide substrate specificity for the ubiquitination reaction, as Cdc20 
and Cdh1 bind substrates independently of the APC/C (Pfleger et al., 2001).  
Substrates are recognised via specific sequences called degrons, most commonly 
the D box (RxxLxxI/VxN/D/E) and KEN box (KENxxxN/D) although there are many 
others (Glotzer et al., 1999; Pfleger et al., 2000).  The co-activators have some 
preference for the specific degrons, with Cdc20 more dependent on the D box for 
substrate-binding and Cdh1 more dependent on the KEN box (Zur and Brandeis, 
2002).  The different, albeit overlapping, substrates of the co-activators means that 
different cell cycle regulators are degraded in the separate phases of APC/C-
Cdc20 and APC/C-Cdh1 activity, giving an ordered progression through the cell 
cycle (Barford, 2011).   However, Cdh1 is not essential for division and only the 
Aurora kinases are stabilised in cells not expressing Cdh1 (Izawa and Pines, 
2011).  Therefore, there must be other factors involved in the temporal regulation 
of substrate degradation. 
  
Part of the answer likely lies in the structural complexity of the APC/C.  It consists 
of at least 13 different protein subunits and has been studied by numerous 
biochemical and structural analyses, including X-ray crystallography of individual 
subunits (Wendt et al., 2001; Zhang et al., 2010), nano-electrospray mass 
spectrometry to analyse molecular weights and stoichiometry (Schreiber et al., 
2011) and cryo-electron microscropy (cryo-EM) of reconstituted APC/C from an 
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overexpression system (Schreiber et al., 2011 [Fig. 4]).  The APC/C can be 
subdivided into three subcomplexes.  The first structural component is the catalytic 
subcomplex, consisting of APC2 (a Cullin-related ubiquitin ligase protein) and 
APC11 (a RING-type ubiquitin ligase) that form a tight complex and are alone 
sufficient to catalyse ubiquitination (Tang et al., 2001).  It also includes APC10, 
which seems to form a co-receptor for the substrate degron (along with the co-
activator), shown by a density bridge linking APC10, co-activator and substrate in 
the cryo-EM structure (Schreiber et al., 2011).  The second subcomplex is 
composed of 3 or 4 layers of subunits containing 34-residue tetratricopeptide 
repeats (TPRs) – APC3, APC6, APC8 and APC7 in higher eukaryotes.  The TPR 
complex mediates co-activator binding to the APC/C.  Finally, APC1, APC4 and 
APC5 form the platform of the APC/C and connect the catalytic and TPR domains.  
The APC/C also interacts with two E2 enzymes – UbcH10 (needed for initiation) 
(Kirkpatrick et al., 2006) and UbE2S (required for elongation) (Garnett et al., 
2009).  Although the role of some of these subunits has recently been elucidated, 






Figure 4 – Model structure of the APC/C 
The structure of the yeast APC/C modelled on X-ray crystallographic structures of 
individual subunits docked onto the cryo-EM structure of the entire complex 
(Schreiber et al., 2011). 
 
Another way that the timing of APC/C substrate ubiquitination is regulated is by the 
Spindle Assembly Checkpoint (SAC).  During mitosis, Securin holds sister 
chromatids together, preventing the onset of anaphase (Funabiki et al., 1996).  
Cdk1-cyclin B1 phosphorylates and inhibits Separase and Cdh1, allowing time for 
the chromosomes to attach to the spindle and correctly align so that each 
chromatid is attached to opposite poles of the cell (Gorr et al., 2005).  APC/C-
Cdc20 then targets Securin and cyclin B1 for degradation, allowing progression 
into anaphase (Zur and Brandeis, 2001).  However, the activity of APC/C-Cdc20 in 
pro-metaphase is inhibited until all chromatids are attached to the mitotic spindle 
(van Zon and Wolthuis, 2010).  An unattached kinetochore triggers activation of 
the SAC to delay onset of anaphase and ensure correct segregation of 
chromosomes.  This is mediated by the Mitotic Checkpoint Complex (MCC), 
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composed of the proteins Mad2, Mad3/BubR1, Bub3, which form an inhibitory 
complex with Cdc20 (Braunstein et al., 2007).  Thus, this pathway ensures the 
APC/C functions in a timely manner during the cell cycle. 
 
However, there are some substrates that escape the SAC, such as cyclin A and 
Nek2A which are degraded upon NEBD.  Cyclin A associates with Cdk1 and Cdk2 
to support progression through S and G2 phases (Pagano et al., 1992), while 
Nek2A is a centrosomal kinase required for the formation of the mitotic spindle 
(Fry et al., 2002).  Live cell imaging first revealed that cyclin A begins to be 
degraded shortly after nuclear envelope breakdown (den Elzen and Pines, 2001), 
with Nek2A behaving similarly (Hames et al., 2001), and so are not affected by the 
SAC.  These two proteins do not contain the conventional degrons and instead 
have different modes of binding to the APC/C.  Cyclin A binds, via its N-terminus, 
to Cdc20 with high enough affinity to out-compete binding of BubR1.  It also binds 
to Cks, the cyclin-dependent kinase cofactor, which recruits the complex to the 
APC/C for ubiquitination (Di Fiore and Pines, 2010).  Nek2A contains a Met-Arg 
dipeptide C-terminal tail, similar to that found on the co-activators, allowing it to 
bind directly to the APC/C, even without Cdc20 (Hayes et al., 2006).  Therefore, 
the MCC only prevents degradation of substrates with true D boxes that are 
dependent on Cdc20 for recruitment.  Depletion of specific APC/C subunits using 
siRNA also revealed that Cdc20 binds to different sites on the APC/C depending 
on the SAC.  When the SAC is active, only APC8 is necessary, whereas both 
APC3 and APC8 are required when the SAC is satisfied.  Furthermore, APC10 is 
only necessary for the degradation of cyclin B1 and Securin, not for cyclin A, 
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suggesting that Cdc20 (at its position bound to APC3 and APC8) works with 
APC10 to provide a binding site for SAC-sensitive substrates only (Izawa and 
Pines, 2011; Fig. 5).  This level of complexity allows the APC/C to actively regulate 
substrate specificity and timing of degradation during the cell cycle.  
Figure 5 – APC/C regulation during early mitosis 
When the SAC is active during prometaphase (left), the APC/C is inhibited by 
Cdc20 binding the MCC.  During this stage, Cdc20 binds to the APC/C via APC8 
and substrates such as cyclin A and Nek2A, which bind directly to the APC/C, can 
be targeted.  In metaphase when the SAC has been satisfied (right), both APC3 
and APC8 are required for Cdc20 binding and APC10 along with Cdc20 forms a 
co-receptor for APC/C substrates such as cyclin B1.  The MCC proteins may 
prevent Cdc20 binding to APC3 and so prevent formation of the binding site for 
SAC-sensitive substrates while the SAC is active (Izawa and Pines, 2011). 
 
 
The APC/C is subject to post-translational modifications (PTMs).  It well known 
that the APC/C is activated by cyclin B1-CDK1 after entry to mitosis by 
phosphorylating the APC/C, mapped to sites in subunits APC3, APC6 and APC8 
in Saccharomyces cerevisiae by mutagenesis (Rudner and Murray, 2000).  It has 
been shown that this phosphorylation (the mitotic form) increases binding of the 
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co-activator Cdc20 (Kramer et al., 1998).  More recently, a total of 71 
phosphorylation sites on the APC/C have been identified, which seem to vary with 
the use of different mitotic arrest drugs (Sheen et al., 2008), indicating a role of 
phosphorylation in regulating of APC/C activity.  Additionally, phosphorylation of 
Cdc20 (by the MCC) and Cdh1 inhibits their binding to the APC/C (Primorac and 
Musacchio, 2013).  It may be that more phosphorylation sites are still to be found 
and recently, the Turnell group has found acetylation of APC/C subunits 
(unpublished data), showing there is more to be done to determine the role of 
PTMs in APC/C regulation. 
 
Recent studies have reported that the APC/C has roles in the cell aside from cell 
cycle regulation.  Experiments in yeast have suggested that the APC/C, 
specifically APC5, is required for chromatin assembly (Harkness et al., 2005).  
Multiple APC/C subunit mutants exhibited impaired total histone H3 levels and 
were also linked to changes in H3 modifications that indicated that specific histone 
acetyltransferases are required for APC/C-dependent cell cycle progression 
(Turner et al., 2010).  In human cells, the APC/C subunits APC5 and APC7 were 
found to interact with the transcriptional activators CBP and p300 (Turnell et al., 
2005).  APC5 and APC7 enhanced CBP/p300-dependent transcription and were 
also found associated with CBP/p300-regulated promoters.  Knockdown of APC5 
and APC7 led to decreased H4 acetylation at promoters, showing they stimulate 
CBP/p300 acetyltransferase activity and thus affect transcription (Turnell et al., 
2005).  These data suggested that different APC/C subunits could have distinct 
functions in the cell. 
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1.1  Hypothesis and Aims 
The aim of the present study was to determine more about the specific functions of 
the individual APC/C subunits – specifically APC5.  Unpublished observations in 
the Turnell laboratory suggest that APC5 protein levels change during the cell 
cycle and that APC5 contains potential degrons within its primary sequence.  It 
was hypothesised that the timely changes in APC5 protein levels are important for 
the regulation of mitotic progression, but the molecular basis of the control of 
APC5 levels is currently unknown.  To further understand the roles of APC5 in the 
cell, the aims this project were as follows: 
1. Validate APC5 protein levels in mitosis 
2. Investigate the stability of APC5 in mitosis 
3. Develop a Tetracycline-inducible FLAG-APC5 system to validate 
results from endogenous proteins 
4. Investigate the role of APC5 phosphorylation in regulation of APC5 
protein levels 
5. Identify APC5 binding partners in chromatin to learn more about the 





2.  MATERIALS AND METHODS  
 
2.1  Cell Culture 
HeLa cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM), modified 
with HEPES and supplemented with 2 mM L-glutamine and 8% (v/v) foetal calf 
serum (FCS), and incubated at 37°C until confluent.  For cell subculture, the 
medium was removed and the cells washed in PBS, before incubating at 37°C 
with trypsin solution (TrypLE express, Gibco) until cells had detached from the 
dish.  Trypsin was inactivated with the addition of DMEM and the cells harvested 
by centrifugation (1500 rpm, 5 mins).  The pellet was resuspended in DMEM and 
plated at the appropriate cell density. 
 
2.2  Cell Synchronisation 
HeLa cells were incubated overnight in DMEM (supplemented with 8% [v/v] FCS 
and 2 mM L-glutamine) and the appropriate concentration of inhibitor: 400 ng/ml 
nocodazole; 1 µM taxol; 9µM RO3306.  Mitotic cells were harvested by shake-off, 
followed by centrifugation (1500 rpm, 5 mins) and the pellet washed in cold saline 
and resuspended in lysis buffer (9 M urea, 50 mM Tris [pH 7.4] and 0.15 M β-
mercaptoethanol).  Asynchronous and G2/M-arrested cells were washed with cold 
saline and harvested by scraping after incubation for 5 mins with lysis buffer. 
 
Where appropriate, a protein synthesis inhibitor (anisomycin,100 µM) or 
proteasome inhibitor (MG132, 10 µM) was added approximately 18 hours following 




For inhibitor release, cells were washed twice in DMEM (8% FCS) and fresh 
medium added, before harvesting (as above) at set time points following release. 
 
2.3  Plasmid Amplification and Purification 
The plasmid DNA (pcDNA5/FRT-3xFLAG-APC5-TR) was first transfected into E. 
coli cells that are recombination- and endonuclease A- deficient.  For bacterial 
transformation, 100 ng of the purified DNA was mixed with 20 µl DH5α E. coli and 
incubated at 42°C for 1 min to heat shock the cells.  0.5 ml LB broth was added to 
the bacteria and thereafter incubated at 37°C for 45 mins, before selecting for 
transformants on LB agar plates containing 100 µg/ml ampicillin.  Bacterial cells 
were transferred to 5 ml LB broth (with 5 µl ampicillin) and grown for 5 hours 
before incubating in 250 ml broth overnight.  The plasmid was purified following 
the manufacturer’s instructions (Sigma maxiprep).  0.1 volume sodium acetate (pH 
5.0) and 0.7 volume isopropanol was added and centrifuged for 30 mins at 9000 
rpm.  The pellet was washed twice in 70% ethanol, before resuspension in the 
appropriate volume of water to dissolve the DNA.  DNA concentration was 
determined using a nanodrop (Thermo Scientific Nanodrop 2000). 
 
2.4  Transfection 
HeLa Tetracycline-responsive Flp-In cells (Life Technologies), that have a Flp 
Recombination Target (FRT) site integrated into the genome, were grown to 
confluence and transferred to OptiMEM (Gibco) low serum medium.  Cells were 
co-transfected using lipofectamine 2000 (Life Technologies) with the 
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pcDNA5/FRT-3xFLAG-APC5-TR vector and a Flp recombinase expression 
plasmid pOG44, according to the manufacturer’s protocol of the Flp-In system 
(Life Technologies).  Transfected cells were subjected to blasticidin/hygromycin 
selection and single colonies selected to give monoclonal cell foci, as well as 
collecting all cells on a single plate to obtain polyclonal cell lines.  The expression 
vector was induced with the addition of either 1 µg/ml or 0.1 µg/ml Doxycycline (a 
stable tetracycline analogue). 
 
2.5  Western Blotting 
Cell lysates were sonicated (Microson Ultrasonic Cell Disrupter) for 10-15 sec at 
power setting 4 and centrifuged for 20 min at 13000 rpm.  The protein 
concentration was determined using a Bradford assay (Bio-Rad) and 50 µg of 
each protein sample was mixed with an equal volume of loading buffer (1 volume 
of 10% w/v SDS to 2 volumes of 9 M urea in 50 mM Tris (pH 7.4) plus 5% (v/v) β-
mercaptoethanol), before boiling for 5 min at 95°C. 
 
The proteins were separated using sodium dodecyl sulphate-polyacrylaminde gel 
electrophoresis (SDS-PAGE) and subsequently transferred to nitrocellulose paper 
using a wet-transfer method.  The membranes were washed using TBST (0.1% 
[v/v] Tween™ 20, 0.2 M sodium chloride [NaCl] and 0.02 M Tris [pH 7.6]) and 
incubated with a blocking agent (5% powered milk or 5% BSA in TBST) for at least 
30 min.  The membranes were placed in bags, sealed with the primary antibody 
(made to the correct dilution in the appropriate blocking agent) (Table 1) and left 
on a rocker for a minimum of 3 hours.  The blots were washed in TBST to remove 
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any unbound antibody and incubated with the appropriate secondary antibody for 
2-3 hours on a shaker.  Blots were washed with TBST on an orbital shaker every 
15 min for 1 hr, before the addition of enhanced chemiluminescent (ECL) 
substrate with hydrogen peroxide for 1-2 min.  The blots were exposed to x-ray 
film for the appropriate time and developed. 
Antibody Dilution Species Blocking 
Agent 
Supplier 
Actin 1:20000 Mouse Milk Sigma 
APC3 1:1000 Mouse Milk BD Biosciences 
APC5 1:1000 Mouse Milk Home-made 
mAB 
APC7 1:2000 Rabbit Milk Home-made 
pAB 
Cdc20 1:1000 Mouse Milk Santa Cruz 
Cdh1 1:1000 Mouse Milk Santa Cruz 
Cyclin A 1:1000 Mouse Milk Santa Cruz 
Cyclin B1 1:1000 Mouse Milk CR-UK 
FLAG 1:1000 Mouse Milk Sigma 
Geminin 1:500 Rabbit Milk Santa Cruz 
H4K8Ac 1:500 Rabbit Milk Life 
Technologies 
Nek2A 1:500 Mouse Milk Abcam 
Phospho-H3 1:500 Rabbit BSA Cell Signalling 
TIF1γ 1:1000 Rabbit Milk Home-made 
pAB 
UbcH10 1:500 Rabbit Milk Home-made 
pAB 
Table 1 – Antibodies used in Western Blotting 
 
2.6  RNA Preparation and RT-qPCR 
RNA was purified using the Qiagen RNeasy Mini Kit, according to manufacturer’s 
instructions.  Briefly, HeLa cells were harvested (as above) using the lysis buffer 
provided (Buffer RLT).  The cells were homogenised by centrifugation at 13200 
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rpm for 2 mins in a QIAshredder spin column (cat. no. 79654).  One volume of 
70% ethanol was added and the sample transferred to an RNeasy spin column, 
before centrifugation at 12000 rpm for 15 secs to leave nucleic acids bound to the 
column.  The sample was then washed in Buffer RW1 and centrifuged at 12000 
rpm for 15 secs, before DNase1 (in Buffer RDD) was added to digest DNA.  The 
sample was again washed with Buffer RW1 and centrifuged (12000 rpm, 15 secs), 
followed by two washes with Buffer RPE, the first centrifuged as before and the 
second for 2 mins at 12000 rpm.  The RNA was eluted from the column by adding 
50 µl of RNase-free water and centrifuging for 1 min at 12000 rpm. 
 
The RNA concentration was measured using a nanodrop (Thermo Scientific 
Nanodrop 2000) and reverse transcription PCR (RT-PCR) performed with the 
Promega Reverse Transcription System.  Water was added to 500 ng RNA to a 
final volume of 4.9 µl and incubated at 70°C for 10 mins.  A master mix was 
prepared using: 2 µl MgCl2, 1 µl 10x RT buffer, 1 µl 10 mM dNTPs, 0.25 µl RNasin 
Ribonuclease Inhibitor, 0.5 µl random primers and 0.3125 µl AMV Reverse 
Transcriptase, per sample, and 5 µl added to each RNA sample.  The tubes were 
incubated at room temperature for 10 mins and one PCR cycle ran at 42°C for 1 
hour, 95°C for 5 mins and 4°C for 5 mins.  Water was then added to the generated 
cDNA to give a final concentration of ~10 ng/µl. 
 
A master mix of 10 µl Taqman 2x MasterMix (Life Technologies), 1 µl Taqman 
Assay Probe and 7 µl water was added to 2 µl cDNA.  The probes used were for 
the genes: APC5 (FAM) and GAPDH (FAM) as a control housekeeping gene.  The 
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qPCR reaction was performed (7500 Real Time PCR System, Life Technologies) 
and the cycle number (Ct) for each sample analysed.  The GAPDH Ct was 
subtracted from the corresponding APC5 Ct to obtain the δCt and the average δCt 
for asynchronous cells subjected from the result, to analyse any changes 
compared to asynchronous cells.  The value was then converted to a percentage 
change in gene expression. 
 
2.7  Chromatin Isolation 
The procedure was carried out as previously described (Wysocka et al., 2001).  
Cells were washed twice with PBS then harvested by scraping and centrifuged at 
1000 rpm for 2 minutes.  The cell pellet was resuspended in Buffer A containing 10 
mM HEPES (pH 7.9), 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% (v/v) 
glycerol, 1 mM DTT and 0.1% (v/v) Triton X-100.  The samples were incubated on 
ice for 8 minutes, before centrifugation (1300 x g, 4°C, 5 min).  The supernatant 
was isolated and centrifuged at 20000 x g, 4°C, for 5 min to give the cytoplasmic 
fraction, while the pellet was washed with Buffer A and incubated for 30 min in 
Buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT) to lyse the nuclear membrane.  
It was then centrifuged at 1700 x g, 4°C, 5 min, to obtain the nucleoplasmic 
fraction (supernatant) and the chromatin fraction (pellet).  A proportion of the 
chromatin fraction was then washed in a salt solution to elute chromatin-binding 
proteins and resuspended in lysis buffer or RIPA buffer (25mM Tris-HCl (pH 7.6), 
150mM NaCl, 1% [v/v] NP-40, 1% [w/v] sodium deoxycholate, 0.1% [v/v] SDS) 




2.8  Immunoprecipitation - Mass Spectrometry (IP-MS) 
Protein samples, prepared in NETN lysis buffer (250 mM NaCl, 20 mM Tris-Cl (pH 
8.0), 0.5 mM EDTA, 0.5 % [v/v] Nonidet P-40 [NP-40]), were split into two: 
antibody was added to one tube and the other left without antibody to act as a 
control for non-specific binding.  The samples were incubated, spinning, overnight 
at 4°C, before the addition of 50µl protein G sepharose beads and incubation for 3 
hours at 4°C on a rotator.  The beads were spun down and washed 4 times with 
NETN lysis buffer and sample buffer added containing 50 mM DTT to elute the 
protein from the beads.  The samples were boiled for 5 min at >80°C, spun down 
briefly and loaded onto NuPAGE 4-12% Tris/Bis-tris gels (Life Technologies) to 
separate the proteins.  The gels were incubated with colloidal coomassie reagent 
overnight to stain the protein bands and then washed several times in 1% (v/v) 
acetic acid to remove background stain.   
 
Individual slices of the gel were then cut out and washed twice in 50% (v/v) 
acetonitrile/ 50 mM ammonium bicarbonate for 45 min to remove the SDS and 
stain from the gel.  The gel was incubated in 50 mM DTT/10% (v/v) acetonitrile/ 50 
mM ammonium bicarbonate at 56°C for 1 hr, followed by incubation in 100 mM 
iodoacetamide/10% (v/v) acetonitrile/50 mM ammonium bicarbonate for 30 min in 
the dark.  The gel slices were washed three times for 15 min in 10% (v/v) 
acetonitrile/40 mM ammonium bicarbonate and dried using a vacuum centrifuge.  
10% (v/v) acetonitrile/40 mM ammonium bicarbonate was added to a trypsin 
solution to activate the enzyme, before incubating with the samples overnight.  
Any liquid, containing the peptides from the gel, was then transferred to a new 
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tube, the gel incubated with 3% (v/v) formic acid on a shaker for 1 hr and the 
process repeated.  The peptides were then dried using a vacuum centrifuge, 
resuspended in 1% (v/v) acetonitrile/1% (v/v) formic acid and run on a quadrupole 
time-of-flight (QTOF) mass spectrometer (maXis Impact, Bruker). Fragmentation 
data produced were then searched against a theoretical database (Mascot, Matrix 




3.  RESULTS 
 
3.1  APC5 Protein Levels are Reduced During Mitosis 
 Previous unpublished studies have suggested that APC5 protein levels vary 
during mitosis.  To validate changes in APC5 levels in mitosis, HeLa cells were 
treated with nocodazole, a spindle inhibitor, to synchronise cells in the prophase 
stage of mitosis.  The cells were then released from nocodazole inhibition, cells 














Figure 6 – Levels of APC/C subunits and substrates in mitosis 
Cells were incubated with nocodazole for 18 hours and released into normal 
medium, before harvesting at set time points between 0 and 6 hours, as shown.  
The cells were lysed, proteins quantified and a Western blot performed to look at 
the relative levels of both APC/C subunits and its known substrates at each time 





The results show a decrease in the levels of APC5 in mitosis, which then begin to 
increase as the cells exit mitosis.  APC3 is present in its phosphorylated mitotic 
form during the early time points, verifying that the cells are in mitosis.  
Furthermore, the levels of known APC/C substrates, Geminin and Nek2A, are 
seen to decrease during the time course, showing that the APC/C is still active 
despite the reduction in APC5 protein.  These data indicate that APC5 protein 
levels are reduced during mitosis.  However, there is still some protein present that 
is resistant to loss, suggesting that different pools of APC5 could be present in the 
cell to perform distinct functions. 
 
3.2  Loss of APC5 Protein is not SAC-Sensitive 
The present study has shown APC5 protein levels are reduced during mitosis (Fig. 
6).  In order to determine the exact timing of APC5 degradation, HeLa cells were 
treated with RO3306 (a Cdk1-inhibitor), nocodazole or taxol (a spindle-stabiliser) 
to synchronise cells at different stages in mitosis (i.e. at G2/M, in pro-metaphase 
before spindle assembly and in anaphase before spindle disassembly).  Western 
blotting was used to compare the levels of APC5 in each of the inhibitor-treated 




























Figure 7 – Levels of APC/C substrates and subunits at different stages in the 
cell cycle 
HeLa cells were grown in normal media with the addition of RO3306, nocodazole 
or taxol for 18 hours, along with asynchronous cells with no cell cycle inhibitor.  
The cells were harvested and lysed, and a Western blot performed to analyse the 
relative levels of APC/C substrates and subunits at varying stages of the cell cycle, 
compared to asynchronous.  Phospho-histone H3 (Ser10) (P-H3) was used to 
indicate the cell cycle stage, being present during mitosis, and β-actin used as a 
loading control.  
 
 
The results show that APC5 levels are reduced compared to asynchronous and 
RO3306-treated cells in both nocodazole- and taxol-synchronised cells.  
Moreover, the levels of APC5 follow a similar pattern to that shown by SAC-
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insensitive APC/C substrates, cyclin A and Nek2A, as opposed to SAC-dependent 
substrates such as cyclin B1 and Geminin.  This suggests that APC5 protein levels 
are not SAC-sensitive.  It may be that APC5, with its possible degron sequences, 
is marked for degradation by the APC/C and thus is a way to self-regulate APC/C.  
APC5 does not seem to contain a C-terminal MR dipeptide sequence like Nek2A 
and a BLAST search revealed no significant sequence similarity between APC5 
and the N-terminal APC/C-binding region of cyclin A.  Thus, APC5 may be 
degraded by a different mechanism. 
 
3.3  APC5 Protein Stability 
APC5 protein levels are seen to decrease during mitosis.  To assess whether this 
is an effect at the level of protein stability, HeLa cells were treated with nocodazole 
for 18 hours to synchronise cells in mitosis, then anisomycin, a protein synthesis 
inhibitor, was added.  The levels of APC5 were monitored at set time points to 
determine the protein half-life in mitotic cells compared to the protein half-life in 
asynchronous cells (Fig. 8a).  
 
The results, however, showed little change in APC5 levels following anisomycin 
treatment.  This was a surprising result as the levels of APC5 have been shown to 
decrease during mitosis, but it is likely that the APC5 level had already reached its 
minimum during nocodazole synchronisation, before anisomycin was applied and 




Therefore, the experiment was repeated using RO3306 to synchronise HeLa cells 
at the G2/M transition.  Cells were simultaneously released, to progress into 
mitosis, and anisomycin added to analyse APC5 half-life from mitotic entry.  Some 
cells were not released and anisomycin added while still inhibited to act as the 
control (Fig. 8b). 
 
Western blotting again showed little change in APC5 levels over time.  This 
indicates that APC5 levels are not altered following RO3306 release, but more 
work is needed to validate this.  An explanation for the mechanisms by which 
APC5 might be reduced during mitosis will be considered in the discussion. 
 
 
Figure 8 – APC5 protein stability in mitosis 
(A)  HeLa cells were grown until confluent and were either treated with nocodazole 
to synchronise in mitosis or were left untreated to remain asynchronous (AS).  
After 18 hours, 100 µM anisomycin (a protein synthesis inhibitor) was applied to 
the cells and the cells harvested at set time points from 0 hour to 4 hours.  
Western blotting was used to monitor the levels of APC5 over time in 
asynchronous compared to mitotic cells.  (B) HeLa cells were treated with 
RO3306, a Cdk1 inhibitor to synchronise cells at G2/M.  After 18 hours, cells were 
either further treated with anisomycin (100 µM) or the cells were released from 
inhibition into fresh media containing anisomycin (100 µM).  Cells were harvested 
at the time points shown and Western blotting used to measure changes in APC5 
protein levels in each sample.  
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To rule out any transcriptional effects for changes in APC5 levels, qRT-PCR was 
used to measure changes in APC5 transcript levels during mitosis.  HeLa cells 
were synchronised in mitosis with nocodazole or taxol, harvested and the RNA 
isolated (as described in Materials and Methods, section 2.6).  The RNA was 
reverse transcribed and a qPCR reaction performed in triplicate with the cDNA 
product using probes for APC5 and GAPDH as a control (Fig. 9). 
 
Figure 9 – Changes in APC5 relative gene expression levels in mitotis 
HeLa cells were treated with nocodazole or taxol for 18 hours to synchronise cells 
in mitosis, harvested and the RNA isolated.  RT-PCR was performed, followed by 
qPCR to analyse quantities of APC5 mRNA, relative to that of the housekeeping 
gene GAPDH.  The experiment was repeated three times and the averages 
determined, with error bars calculated using the standard deviation.  Statistical 
analysis revealed a significant difference between asynchronous and taxol-treated 
cells (significant at p<0.05). 
 
The results for the taxol samples (although the RNA obtained in the third repeat 
was too dilute to be of use) showed a significant increase in the expression of the 
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APC5 gene in mitotic compared to asynchronous cells, with a T test score of 
0.0224.  These data support the hypothesis that the changes seen in APC5 occur 
at the level of protein stability, as opposed to changes in transcription levels.  It is 
difficult to draw conclusions from the data for the nocodazole samples, as the high 
variance between the three repeats skewed the T test and suggested no 
significant change (0.349), however there does not appear to be a decrease in 
APC5 mRNA levels, again supporting the hypothesis.  This experiment would 
need to be repeated to draw firm conclusions about levels of APC5 gene 
expression in mitosis.  
 
3.4  FLAG-APC5 Protein Levels are Reduced in Mitosis 
Experiments so far have indicated that APC5 protein levels are reduced in mitosis.  
To validate these findings, a cell line was created that expressed FLAG-tagged 
APC5.  HeLa Flp-In cells were transfected with a vector containing the sequence 
for FLAG-tagged APC5, which was integrated into the genome using the Flp 
recombinase enzyme.  Expression of FLAG-APC5 was induced using Doxycyclin, 
while retaining expression of the endogenous APC5 protein.  Expression of FLAG-
APC5 was verified in three polyclonal strains by Western blotting following 
Doxycyclin treatment for 24 or 48 hours (Fig. 10).  The results show all three 
clones express FLAG-APC5 and that 24 hours induction is sufficient.  Both 

















Figure 10 – Expression of FLAG-tagged APC5 in transfected HeLa FRT cells 
Polyclonal HeLa FRT cells containing the gene encoding FLAG-tagged APC5 
were generated and grown until confluent in blasticidin- and hygromycin- 
containing media. Doxycycline (Dox) was used at either 0.1 or 1 µg/ml to induce 
expression of the FLAG-APC5 in each population (1, 2 and 3).  Cells were 
harvested after 24 and 48 hours, lysed and the protein concentration measured.  
Western blotting was used to monitor levels of FLAG-APC5 protein, along with 
endogenous APC5 (endog.).  
 
 
Cells from each clone were treated with Doxycyclin for 24 hours, before addition of 
nocodazole or taxol to synchronise cells in mitosis.  The cells were harvested and 
Western blotting used to investigate changes in the levels of FLAG-APC5 and 

































Figure 11 – FLAG-APC5 levels decrease in mitosis 
Polyclonal HeLa FRT cells, containing the gene for FLAG-tagged APC5 were 
treated with 1 μg/ml doxycycline for 24 hours to induce FLAG-APC5 expression, 
before the addition of either nocodazole or taxol for 18 hours to arrest cells in 
mitosis.  Mitotic cells were harvested by knock-off, lysed and the protein 
concentration measured.  Western blotting was performed to analyse levels of 
FLAG-APC5 and endogenous APC5 in each condition compared to that in 
asynchronous (AS) cells.  APC3 and UbcH10 were used to indicate mitotic arrest, 




The results show a decrease in FLAG-APC5 levels upon treatment with both 
nocodazole and taxol, similar to that seen for endogenous APC5.  The decrease in 
FLAG-APC5 levels compared to asynchronous cells may be less than that 
observed for endogenous APC5 due to the continued transcription of FLAG-APC5 
during mitosis.  However, these results suggest that FLAG-APC5 protein levels 




The Western blots for APC3 and UbcH10 confirm that the cells are in mitotic 
arrest, with APC3 showing a mitotic phosphorylated form and UbcH10 levels 
increasing.  However, APC3 shows lower levels than that normally seen and 
UbcH10 demonstrates a second band, perhaps a splice variant.  These changes 
suggest that FLAG-APC5 could be having an effect on the APC/C and there may 
be further differences in these cells compared to HeLa cells. 
 
Three monoclonal strains of FLAG-APC5-containing HeLa FRT cells were also 
generated and the expression of FLAG-APC5 verified (Fig. 12).  Although these 
cell lines should be genetically identical, due to having the same point of genome 











Figure 12 – Expression of FLAG-tagged APC5 in transfected HeLa FRT 
monoclonal cells 
HeLa FRT cells were transfected with a plasmid containing the sequence for 
FLAG-tagged APC5, along with a Flp Recombinase target site, to allow genome 
integration.  Cells were selected using blasticidin and hygromycin and individual 
cell colonies isolated and grown to confluence.  The FLAG-APC5 gene was 
induced using doxycycline (Dox) at either 0.1 or 1 µg/ml and cells harvested after 
24 hours, lysed and the protein concentration measured.  Western blotting was 




3.5  Phosphorylation Status of APC5 in Mitosis 
This study has so far shown that, although APC5 protein levels are reduced during 
mitosis, a proportion of the protein remains.  From this, one hypothesis is that 
different pools of APC5 are performing different functions in the cell, of which 
some are degraded in mitosis.  It might be that APC5 has different post-
translational modifications, thus distinguishing the proteins and marking them for 
degradation.  As phosphorylation of APC/C subunits is known to be important in 
regulation, APC5 could be differentially phosphorylated.  To investigate the 
phosphorylation status of APC5 in mitosis, MG132, a proteasome inhibitor, was 
used to enable analysis of the phosphorylation of the APC5 that is normally 
degraded in mitosis.  Mass spectrometry was to be used to analyse the 
phosphorylation status of APC5 from mitotic cells treated with MG132, compared 
to those without MG132 treatment. 
 
To confirm MG132 does indeed prevent APC5 degradation, cells were first 
synchronised with nocodazole or taxol for 18 hours, before addition of MG132.  
Western blotting was used to measure the levels of APC5 (Fig. 13a).  However, 
although a slight increase in Nek2A was seen with MG132 in asynchronous and 
nocodazole/taxol-treated cells, there was little change in the levels of APC5 upon 
addition of MG132.  This result may have been due to most of the APC5 already 
being degraded following nocodazole treatment, before the MG132 was added. 
 
To investigate this possibility, nocodazole/taxol and MG132 were added 
simultaneously to HeLa cells and the procedure repeated (Fig. 13b).  The results 
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showed MG132 treatment restored levels of both APC5 and Nek2A to 
asynchronous levels.  Taken together, these data suggest that APC5 is targeted 
for degradation by the 26S proteasome in nocodazole/taxol-treated cells.  
However, the results for APC3 demonstrate a loss of its phosphorylation (Fig. 
13b).  Recent work in the laboratory has also found a decrease in protein 
phosphorylation levels by mass spectrometry (Minshall and Turnell, unpublished), 
suggesting that MG132 interferes with cellular phosphorylation status.  
Unfortunately, therefore, the experiment to investigate phosphorylation status 



































Figure 13 – Changes in the levels of APC/C substrates and subunits 
following inhibition of the proteasome  
(A)  HeLa cells were either untreated or subjected to treatment with nocodazole or 
taxol for 18 hours to induce mitotic arrest, before addition of the proteasome 
inhibitor MG132 to half of the cells.  Cells were lysed and the relative levels of 
some APC/C subunits and substrates compared + or – 10 µM MG132, in mitotic 
and asynchronous cells, using Western blotting.  β-actin was used as a loading 
control.  (B)  As for (A), except the nocodazole/taxol and MG132 were added 






3.6  APC5 Binds to Chromatin 
Previous studies have implicated APC5 in transcriptional regulation and chromatin 
structure.  To further investigate the roles of APC5 outside the APC/C, HeLa cells 
were harvested, chromatin isolated and the levels of APC5 and APC/C subunits in 
each cellular fraction measured using Western blotting (Fig. 14). 
 
Figure 14 – Levels of APC/C subunits in different cellular fractions 
HeLa cells were grown until confluent and harvested, before undergoing chromatin 
isolation.  Samples were collected from each fraction and protein concentration 
measured.  Western blotting was used to investigate the levels of APC/C subunits 
and co-activator proteins in each cellular fraction.  TIF1γ was used as a control 
because it is known to bind chromatin, H4K14ac was used to confirm the presence 
of chromatin in the corresponding fractions and β-actin was used as a loading 
control.  * - expected molecular weight band for APC5; ** - observed higher 




The results show that APC5 is found in all cellular fractions, including on the 
chromatin and can be eluted from the chromatin with the addition of salt.  
Interestingly, a second band for APC5 is present in the chromatin fractions 
indicating a higher molecular weight protein.  This is likely to be either: non-
specific antibody binding, a splice variant or post-translationally-modified APC5 
(such as poly-ubiquitination, which could give such an increase in molecular 
weight).  Furthermore, the APC/C subunits APC3 and APC7 are located mostly in 
the chromatin fractions (Fig. 14).  A difference is seen between the locations of the 
two co-activators – Cdc20 is found in the chromatin, whereas there is almost no 
Cdh1, which is instead found in the nucleoplasm.  This indicates that the function 
of the APC/C in chromatin is co-activator specific. 
 
To investigate whether the higher molecular weight protein present in the APC5 
blot was an APC5 species, the chromatin preparation procedure was repeated 
using HeLa Flp-In cells expressing FLAG-APC5 and Western blotting used to see 




Figure 15 – FLAG-APC5 is modified in chromatin 
HeLa Flip-In cells containing the FLAG-APC5 gene were grown in the presence of 
Doxycylin for 24 hours to induce expression before being harvested and 
undergoing a chromatin isolation procedure. Protein concentration from each 
cellular fraction was measured and a Western blot performed to investigate the 
levels of FLAG-APC5 and endogenous APC5, plus APC/C co-activator proteins, in 
each cellular fraction.  TIF1γ was used as a control because it is known to bind 
chromatin, H4K14ac was used to confirm the presence of chromatin in the 




The results do not show the distinct second band previously seen for APC5, but a 
number of higher molecular weight bands are seen in both the APC5 and FLAG-
APC5 blots, indicating that APC5 and FLAG-APC5 are post-translationally 
modified in chromatin.  Therefore, the band may be due to post-translational 
modifications on APC5, such as polyubiquitination, and the band is unlikely to be 
non-specific antibody binding.  The difference seen between the two cell types 
might be because of the FLAG-tag disrupting normal APC/C function and APC5 
modifications. 
 
Moreover, there is also a change in the levels of the co-activators following FLAG-
APC5 expression (Fig. 15).  Cdh1, previously only found in the cytoplasm and 
nucleoplasm in HeLa, is now mostly located in the chromatin fractions of the 
FLAG-APC5-expressing Flp-In cells.  Multiple bands of Cdc20 (as well as TIF1γ) 
can also be observed in the FLAG-APC5 cells.  This suggests there could be 
inherent differences between the cells, making the findings difficult to compare.  
These results indicate, however, that the APC/C associates with chromatin. 
 
3.7  Function of APC5 in Chromatin 
APC5 has previously been found to bind to chromatin (Harkness et al., 2005; 
Turnell et al., 2005; Turner et al., 2010) and results here confirmed the 
association.  To further investigate the role of APC5 in chromatin, the binding 
partners of APC5 in chromatin were identified using IP-MS.  HeLa cells were 
harvested and a chromatin preparation procedure carried out.  APC5 IPs were 
completed using the nucleoplasm, solute from chromatin washed with 0.25 M 
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NaCl and salt-extracted chromatin resuspended in RIPA.  Mass spectrometry was 
performed with the IP products and lists compiled of the proteins present, which 
were then analysed to account for non-specific binding, by comparison to a protein 
G-only control (Fig. 16).  A large number of proteins were identified in the 0.25 M 
NaCl-washed chromatin sample, thus proteins particularly involved with gene 
expression were selected for analysis (Fig. 16b).  A full list of the proteins 






































Figure 16 – APC5 IP-MS reveals possible new functions for the APC/C in 
chromatin 
HeLa cells were grown until confluent, harvested and used in a chromatin 
preparation procedure.  APC5 IP experiments were performed from three cell 
fractions: (A) nucleoplasm, (B) solute obtained from chromatin washed with 0.25M 
NaCl and (C) salt-extracted chromatin resuspended in RIPA buffer.  Mass 
spectrometry was performed with the IP products.  Fragmentation patterns were 
processed and compared to a protein database to identify the proteins present.  
Lists were compiled and analysed to account for non-specific binding, by 
comparison to a protein G- only control, and obvious contaminants were removed.  
A large number of proteins were identified in the 0.25M NaCl-washed chromatin 
sample (B), thus those proteins particularly involved with gene expression were 
selected for clarity.  The lines between proteins indicate known interactions, with 
the different types of evidence colour-coded as indicated. 
Diagrams were prepared using STRING 9.1 (string-db.org)  
 
 
APC/C IPs from the nucleoplasmic fraction have been well studied and the results 
here provide a control for the method by confirming that APC/C subunits can be 




The results from the salt-washed chromatin sample revealed possible novel APC5 
interactions with a range of proteins (Fig. 16b).  These include proteins involved 
with transcriptional regulation, such as the histone modifiers HDAC1/2 and 
DMAP1, which mediate transcriptional repression, and a transcription factor called 
YY1, which acts on a variety of genes.  NONO was also identified: a protein 
implicated in transcriptional regulation and splicing that has also been found to 
interact with HDAC1/2, showing a transcriptional regulation network that APC5 is 
potentially involved with.  Furthermore, a number of proteins implicated in pre-
mRNA processing were identified, including splicing factors such as SF3A3 and 
PRPF31 and an RNA helicase DHX38, plus an RNA exosome component 
(EXOSC4) and factors for mRNA export from the nucleus (DDX19B).  Additionally, 
several proteins required for translation initiation were detected e.g. EIF2A, EIF3J.  
This suggests the APC/C could have additional functions in the cell. 
 
Few results were obtained from the chromatin fraction (Fig. 16c), due to the 
difficulty of performing IPs for proteins within chromatin and the insolubility of 
chromatin.  However, these data support roles for the APC/C in chromatin, such 
as in transcriptional regulation, and provide potential new areas for investigation to 






4.  DISCUSSION 
 
 
Levels of the APC/C subunit, APC5, have been seen to change during mitosis, 
leading to the hypothesis that these changes are important in mitotic regulation.  In 
this study, the use of nocodazole and taxol inhibitors to synchronise HeLa cells in 
mitosis has revealed a decrease in APC5 protein levels in mitosis (Fig. 7).  This 
decrease in APC5 is controlled at the protein level by degradation, shown by 
prevention of the APC5 loss with the use of the proteasomal inhibitor MG132 (Fig. 
13b) (as opposed to a reduction in gene expression, as suggested by qRT-PCR 
[Fig. 9]).  However, the protein responsible for targeting APC5 for degradation is 
still unknown.   
 
Experiments to determine the half-life of APC5 following release into mitosis 
revealed little change in APC5 levels over time (Fig. 8).  One possible explanation 
of these data is that APC5 degradation is linked to the SAC.  In nocodazole/taxol- 
treated cells, there is robust activation of the SAC as it is activated in each cell and 
at every kinetochore in the cell.  In RO3306-released cells, however, there is a 
gradual activation of the SAC, both between cells and within each cell as each 
kinetochore attaches individually, mimicking normal progression.  Thus, it may be 
that a robust SAC is required to observe the decrease in APC5 levels.  APC5 
could be targeted for degradation locally (at individual kinetochores) in order to 
promote the SAC and inhibit APC/C activity to prevent the cell’s transition to 
anaphase until all chromosomes are aligned correctly on the spindle.  
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Consequently, the staggered APC5 degradation in the cell population means little 
variation is seen in the Western blot results.   
 
It is possible that the APC/C self-regulates, supported by the presence of possible 
degrons in the APC5 primary sequence and that APC5 degradation is SAC-
independent with levels following a similar pattern to that of known SAC-
insensitive APC/C substrates such as Nek2A and cyclin A (Fig. 7).  On the other 
hand, it could be targeted for degradation by other ubiquitin ligases, such as an 
SCF protein, for example β-TRCP which is known to be active in mitosis 
(Nakayama and Nakayama, 2005).  To investigate these possibilities, APC/C 
inhibitors, such as proTAME, could be used to see if there are changes in APC5 
levels in mitosis.  The identified potential degrons could also be mutated to see if 
protein stability is affected.   
 
In addition, the involvement of APC5 in the SAC could be further studied.  This 
was hypothesised with the assumption that the cells were effectively synchronised 
and released.  Figure 7 suggests that RO3306 brings about G2/M inhibition 
successfully, but further experiments are needed to verify that the cells here were 
indeed being released and progressing into mitosis.  Therefore, the RO3306-
release half-life experiments should be repeated and the progression into mitosis 
additionally verified by monitoring mitotic indicators such as phosphorylation of 
APC3 and degradation of cyclin B1.  FACS analysis could also indicate effective 
inhibition of cells with RO3306 (at 4n), as well as release through mitosis.  
Secondly, real-time fluorescence microscopy, using fluorescently-labelled APC5 
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(such as previously used to study cyclin A degradation [den Elzen and Pines, 
2001]), could be used to study both the timing of APC5 degradation during mitosis, 
providing more insight into function, and the involvement in the SAC by indicating 
any local degradation of APC5 near kinetochores.  
 
However, not all of the APC5 present in cells is degraded in mitosis.  Half-life 
experiments in nocodazole-treated cells indicated that the remaining protein is 
very stable (Fig. 8a).  These data suggest that this pool of APC5 may be 
performing a distinct function, possibly distinguished by different post-translational 
modifications or subcellular location.  One of the functions of APC5 aside from the 
APC/C is involved with chromatin structure and transcriptional regulation 
(Harkness et al., 2005; Turnell et al., 2005; Turner et al., 2010).  Western blotting 
revealed APC5 bound to chromatin in HeLa cells, but also revealed a second 
higher molecular weight band in the chromatin fractions (Fig. 14), which could 
indicate either non-specific antibody binding, a splice variant or post-translational 
modification such as polyubiquitin, approximated from the increase in molecular 
weight.   
 
Polyubiquitin has many roles in the cell beyond protein degradation, with various 
types of chains consisting of linkages through all seven lysines in its sequence, as 
well as the N-terminal methionine, and can be branched or non-branched (Kessler, 
2013).  This allows it to perform different functions e.g. K63 polyubiquitination 
plays a key role in cell signalling (NFκB activation) and DNA repair, while K11- or 
K48-linked chains target proteins for degradation (Kulathu and Komander, 2012; 
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Matsumoto et al., 2010).  Therefore, it is plausible that polybiquitin is involved in 
APC5 function in chromatin.  Alternatively, many TFs are destroyed by ubiquitin-
mediated proteolysis, such as Myc.  Both stable and unstable pools of Myc are 
present in cells (Tworkowski et al., 2002) and the region signalling ubiquitin-
mediated proteolysis overlaps with the transcriptional activation region. A close 
correlation between the ability of the activation domain to activate transcription and 
to signal proteolysis has also been reported (Salghetti et al., 2000).  Thus, 
polyubiquitination of APC5 and its degradation could be linked to its ability to act 
as a transcriptional activator.   
 
The next step would be to perform a Western blot for ubiquitin on APC5 in 
chromatin to verify its presence.  siRNA could also be used to knock down APC5 
and see if the higher molecular weight band is still observed to rule out any non-
specific antibody effects.  Multiple bands were also seen for cells expressing 
FLAG-APC5 (Fig. 15), supporting post-translational modification.  However, the 
bands were less distinct and blots for other proteins were also different, 
suggesting there could be innate differences between the cells or the FLAG-tag 
could be interfering with normal function.  The next experiment would be to check 
that FLAG-APC5 is incorporated into the APC/C using IP-Western blotting (to 
detect interactions with APC/C subunits) and that it is still functional using in vitro 
activity assays (looking at ubiquitination of target substrates with purified APC/C 
components).  This could be followed by a repeat of the Western blot to verify the 




The function of APC5 in chromatin was further investigated using IP-MS (Fig. 16).  
It was found to interact with TFs and histone modifiers, consistent with previous 
findings of APC5 as a transcriptional regulator (Turnell et al., 2005) and 
suggesting some possible new gene targets.  Some of the histone modifiers 
included HDAC1/2.  Previous studies have found that some APC/C subunits are 
acetylated (Turnell laboratory, unpublished) and this may be associated with 
different times of the cell cycle or different activities.  Thus, it may be hypothesised 
that the HDACs not only deacetylate histones, but can also act on the APC/C to 
regulate activity in different stages of the cell cycle.  This could be further 
investigated by monitoring the association of APC/C subunits to HDAC1/2 in 
different stages of the cell cycle, using cell cycle inhibitors, by Western blotting.  It 
is also consistent with past findings that the APC/C can modulate 
acetyltransferase activities in chromatin and can lead to altered histone acetylation 
patterns in yeast (Turnell et al. 2005; Turner et al., 2010).  Moreover, the MS 
results suggest additional functions of the APC/C, perhaps in RNA processing and 
translation regulation, consistent with past studies that have reported interactions 
of APC5 with the poly(A) binding protein, which is bound to the internal ribosome 
entry site on mRNA, leading to repression of translation (Koloteva-Levine, et al., 
2004).  However, all interactions need to be first validated by IP-Western blotting. 
 
Western blotting with various cellular fractions from HeLa cells also revealed an 
interesting pattern of co-activator localisation.  A large proportion of Cdc20 was 
found bound to chromatin (eluting with 0.25 M NaCl), whereas very little Cdh1 was 
found in the chromatin fractions, with the majority present in the nucleoplasm (Fig. 
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14), suggesting that the chromatin functions of the APC/C could be co-activator 
specific.  The APC/C has been reported to interact with p300/CBP to regulate 
transcription of a gene (Turnell et al., 2005).  More recently, Cdc20 was 
discovered to modulate the transcriptional activity of the APC/C-CBP/p300 
complex to positive regulate expression of UBCH10 expression and was found 
bound to the promoter region (Nath et al., 2011).  Therefore, this result is 
consistent with past findings.  However, a different pattern of localisation of the two 
co-activators was seen when a polyclonal HeLa FRT cell line expressing FLAG-
tagged APC5 was used (Fig. 15).  The differences could be due to inherent 
differences between the cell lines (as multiple bands were seen for Cdc20 too) or 
the FLAG-tag could be interfering with normal APC/C regulation, for example 
tightly binding to Cdh1 and bringing it down to the chromatin.  The experiments 
would need to be repeated with both cell lines and the monoclonal HeLa FRT 
cells, as well as possibly investigating differences compared to other cell lines, e.g. 
A549.  Chromatin Immunoprecipitation could be used to verify co-activator binding 
to chromatin and reveal binding sites in the DNA to determine any possible gene 
targets. 
 
It is possible that the different pools of APC5 are distinguished by different post-
translational modifications, such as phosphorylation which is common in the 
APC/C.  To study this, a proteasome inhibitor MG132 was used to enable analysis 
of the marks on normally degraded APC5 proteins.  Although APC5 degradation 
was prevented, the phosphorylation status of the cell seemed to be affected (Fig. 
13b) and so the experiment could not continue in the time available.  The 
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procedure could be repeated using another proteasome inhibitor e.g. MG115, 
followed by MS to observe APC5 phosphorylation levels and determine the 
specific sites of phosphorylation. 
 
In conclusion, this study has shown that APC5 is degraded during mitosis, in a 
SAC-insensitive manner, which may be involved in APC/C regulation and control 
of mitotic progression.  APC5 has been found to bind to chromatin and possible 
new functions for the APC/C in chromatin identified.  However, there are many 
more questions yet to answer, including identifying the protein responsible for 
targeting APC5 for degradation and investigating the role of post-translational 
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6.  APPENDIX – APC5 IP-MS Data 
 
HeLa cells were grown until confluent, harvested and used in a chromatin 
preparation procedure.  APC5 IP experiments were performed from three cell 
fractions: nucleoplasm, solute from 0.25M NaCl-washed chromatin and salt-
extracted chromatin resuspended in RIPA buffer.  In-gel tryptic digest was 
performed on the IP products, before running on a mass spectrometer.  
Fragmentation patterns were processed and compared to a protein database to 
identify the proteins present.  Lists were compiled and analysed to account for 
non-specific binding, by comparison to a protein G- only control, and obvious 
contaminants were removed.  Full protein lists obtained for each fraction are 
shown below.  
6.1  Nucleoplasm 
Accession Protein Scores #Peptides 
APC1_HUMAN 
Anaphase-promoting complex subunit 1 





Cell division cycle protein 16 homolog 





E3 ubiquitin-protein ligase UBR5 OS=Homo 





Histone H3.2 OS=Homo sapiens 





Anaphase-promoting complex subunit 4 





A-kinase anchor protein 8-like OS=Homo 






methyltransferase OS=Homo sapiens 





Anaphase-promoting complex subunit 5 





Importin subunit alpha-7 OS=Homo sapiens 





DNA polymerase epsilon catalytic subunit A 





Transcription elongation factor B polypeptide 






6.2  Chromatin + 0.25 M NaCl 
 
Accession Protein Scores #Peptides 
NONO_HUMAN 
Non-POU domain-containing octamer-
binding protein OS=Homo sapiens 






ribonucleoprotein L-like OS=Homo 





Apoptosis inhibitor 5 OS=Homo sapiens 





T-complex protein 1 subunit eta 






Histone deacetylase 1 OS=Homo 





Ras GTPase-activating protein-binding 
protein 1 OS=Homo sapiens 





Poly(rC)-binding protein 3 OS=Homo 





EH domain-containing protein 2 






Eukaryotic translation initiation factor 3 






Histone deacetylase 2 OS=Homo 





T-complex protein 1 subunit zeta 






T-complex protein 1 subunit beta 






Guanine nucleotide-binding protein G(k) 
subunit alpha OS=Homo sapiens 





Negative elongation factor C/D 






Far upstream element-binding protein 3 






Leucine-rich repeat protein SHOC-2 






Polypyrimidine tract-binding protein 2 










Histone H3.2 OS=Homo sapiens 





Anaphase-promoting complex subunit 7 






Nucleolar protein 58 OS=Homo sapiens 





Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1 OS=Homo 





Protein SEC13 homolog OS=Homo 





Sorting nexin-27 OS=Homo sapiens 





DNA-directed RNA polymerase I subunit 






Putative 40S ribosomal protein S10-like 






26S proteasome non-ATPase regulatory 
subunit 3 OS=Homo sapiens 





Protein SON OS=Homo sapiens 





Splicing factor 3A subunit 3 OS=Homo 





ATP-dependent RNA helicase SUPV3L1, 
mitochondrial OS=Homo sapiens 






PP1-beta catalytic subunit OS=Homo 





RNA-binding protein Raly OS=Homo 





U4/U6 small nuclear ribonucleoprotein 







PP1-gamma catalytic subunit OS=Homo 





EH domain-containing protein 4 






Lysine-specific demethylase 3B 






ATP-dependent RNA helicase DDX19B 






Importin subunit alpha-7 OS=Homo 








dependent RNA helicase PRP16 






Ensconsin OS=Homo sapiens 





PERQ amino acid-rich with GYF domain-
containing protein 2 OS=Homo sapiens 





Nuclear pore glycoprotein p62 OS=Homo 






PP1-alpha catalytic subunit OS=Homo 





Tyrosyl-tRNA synthetase, cytoplasmic 






Cytoplasmic FMR1-interacting protein 1 






Cytoskeleton-associated protein 4 






Probable ATP-dependent RNA helicase 






DNA mismatch repair protein Msh3 






Importin subunit alpha-2 OS=Homo 





H/ACA ribonucleoprotein complex 






Eukaryotic translation initiation factor 5B 






ATP-binding cassette sub-family D 
member 3 OS=Homo sapiens 





Protein TBRG4 OS=Homo sapiens 





Eukaryotic translation initiation factor 4 
gamma 2 OS=Homo sapiens 





Eukaryotic translation initiation factor 2A 






Probable ATP-dependent RNA helicase 








Methionine aminopeptidase 2 OS=Homo 





Copine-3 OS=Homo sapiens 





Transcriptional repressor protein YY1 





Engulfment and cell motility protein 2 






DNA-directed RNA polymerases I, II, and 
III subunit RPABC3 OS=Homo sapiens 





FK506-binding protein 15 OS=Homo 





Cell division cycle protein 16 homolog 






Histone H2A type 2-B OS=Homo sapiens 





Ribosomal protein S6 kinase alpha-3 






Importin subunit alpha-1 OS=Homo 





Casein kinase I isoform alpha OS=Homo 





Cell division protein kinase 7 OS=Homo 





General transcription factor 3C 
polypeptide 5 OS=Homo sapiens 





Protein DEK OS=Homo sapiens 





Ubiquitin carboxyl-terminal hydrolase 14 






Anaphase-promoting complex subunit 1 







RNA-activated protein kinase OS=Homo 





Exosome complex exonuclease RRP41 






DNA repair protein XRCC1 OS=Homo 





Inositol 1,4,5-trisphosphate receptor type 








Zinc finger protein-like 1 OS=Homo 





Probable ATP-dependent RNA helicase 






Pre-mRNA-splicing factor ISY1 homolog 






Signal recognition particle 72 kDa protein 






Anaphase-promoting complex subunit 2 






Tyrosine-protein kinase Lck OS=Homo 





Pre-mRNA-processing factor 19 






Eukaryotic translation initiation factor 3 






Ribosome production factor 2 homolog 






ATP-dependent RNA helicase DDX55 






80 kDa MCM3-associated protein 






F-box-like/WD repeat-containing protein 
TBL1XR1 OS=Homo sapiens 





39S ribosomal protein L14, mitochondrial 







actin-dependent regulator of chromatin 
subfamily D member 2 OS=Homo 





Nuclear pore complex protein Nup153 






RNA-binding protein PNO1 OS=Homo 





Ubiquitin-conjugating enzyme E2 S 








Programmed cell death 6-interacting 
protein OS=Homo sapiens 





GMP synthase [glutamine-hydrolyzing] 






Protein FAM98A OS=Homo sapiens 





Transformer-2 protein homolog alpha 






Replication protein A 14 kDa subunit 






Carnitine O-palmitoyltransferase 1, liver 






Selenocysteine-specific elongation factor 






Coatomer subunit beta OS=Homo 





Serine/threonine-protein phosphatase 2A 
65 kDa regulatory subunit A alpha 
isoform OS=Homo sapiens 





U4/U6.U5 tri-snRNP-associated protein 2 






ER lumen protein retaining receptor 2 






MKI67 FHA domain-interacting nucleolar 
phosphoprotein OS=Homo sapiens 





U4/U6 small nuclear ribonucleoprotein 






Protein SDA1 homolog OS=Homo 











General transcription factor IIH subunit 1 






Syntaxin-binding protein 1 OS=Homo 





Importin subunit alpha-4 OS=Homo 







Caseinolytic peptidase B protein 






CWF19-like protein 1 OS=Homo sapiens 





Acyl-coenzyme A thioesterase 13 






WD repeat-containing protein 5 






Solute carrier family 35 member E1 






LAG1 longevity assurance homolog 2 






General transcription factor IIE subunit 1 






60S ribosome subunit biogenesis protein 
NIP7 homolog OS=Homo sapiens 





Transcription factor RFX3 OS=Homo 





26S proteasome non-ATPase regulatory 
subunit 14 OS=Homo sapiens 





RNA-binding protein 12B OS=Homo 












Isocitrate dehydrogenase [NAD] subunit 
alpha, mitochondrial OS=Homo sapiens 











Serine/threonine-protein kinase OSR1 






Nucleoporin Nup37 OS=Homo sapiens 





POU domain, class 2, transcription factor 






WD repeat-containing protein 3 








CDK-activating kinase assembly factor 






DNA methyltransferase 1-associated 
protein 1 OS=Homo sapiens 





SOSS complex subunit C OS=Homo 





Eukaryotic translation initiation factor 2 
subunit 1 OS=Homo sapiens 





Secretory carrier-associated membrane 
protein 2 OS=Homo sapiens 





Probable RNA-binding protein 46 






26S proteasome non-ATPase regulatory 
subunit 1 OS=Homo sapiens 





Origin recognition complex subunit 2 






Protein mago nashi homolog OS=Homo 





Neurofibromin OS=Homo sapiens 





Vacuolar protein sorting-associated 
protein 16 homolog OS=Homo sapiens 





Transitional endoplasmic reticulum 






Nuclear factor 1 C-type OS=Homo 





THO complex subunit 4 OS=Homo 





Nucleus accumbens-associated protein 1 






Schlafen family member 5 OS=Homo 





Protein transport protein Sec61 subunit 






Calreticulin OS=Homo sapiens 





General transcription factor IIH subunit 4 









Neuroguidin OS=Homo sapiens 





Exosome complex exonuclease MTR3 






Non-homologous end-joining factor 1 






Protein YIF1B OS=Homo sapiens 





Nuclear-interacting partner of ALK 






Enhancer of mRNA-decapping protein 4 






PHD finger-like domain-containing 
protein 5A OS=Homo sapiens 





Vacuolar protein sorting-associated 
protein 53 homolog OS=Homo sapiens 





Netrin receptor UNC5B OS=Homo 





5-azacytidine-induced protein 1 






Dedicator of cytokinesis protein 5 






AP-1 complex subunit mu-1 OS=Homo 





60S ribosomal protein L3-like OS=Homo 





COP9 signalosome complex subunit 6 






Serine/threonine-protein kinase 12 






Ribosomal L1 domain-containing protein 






Golgin subfamily A member 7 OS=Homo 





Leucine-rich repeat-containing protein 47 















6.3  Salt-Extracted Chromatin 
Accession Protein Scores #Peptides 
APC5_HUMAN 
Anaphase-promoting complex subunit 5 






Anaphase-promoting complex subunit 1 






Histone H2A type 1-H OS=Homo sapiens 





Histone H1.2 OS=Homo sapiens 





Microsomal glutathione S-transferase 3 





Rab effector Noc2 OS=Homo sapiens 





Nucleolar protein 58 OS=Homo sapiens 





Synaptotagmin-like protein 4 OS=Homo 





DNA polymerase epsilon catalytic subunit A 





Sodium bicarbonate cotransporter 3 






NHP2-like protein 1 OS=Homo sapiens 





Microsomal glutathione S-transferase 1 





Cell division cycle protein 23 homolog 
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Glioblastoma (GBM) is the most common and most aggressive form of brain 
cancer.  Current treatment involves concomitant radiotherapy and chemotherapy 
with the drug Temozolomide (TMZ), but the median survival is still only around a 
year.  Transcriptional profiling studies revealed different subtypes of GBM with 
distinct patterns of gene expression that are linked to specific genetic alterations.  
In this study, cell lines were used to represent the different subtypes.  They were 
cultured as 3D spheroids, which have been shown to be more representative of 
GBM tumours than monolayers.  Confocal imaging of polyclonal spheroids showed 
the subtypes form distinct populations that reflect their preference for different 
positions within the spheroid, suggesting an arrangement that confers a survival 
advantage to the cells.  The effect of TMZ treatment was studied, with different 
effects seen both between 2D and monoclonal spheroid culture, and between the 
different subtypes with varying morphological changes following treatment.  The 
results show that spheroid culture is a promising method in GBM model 
development.  However, problems were encountered that hindered imaging of 
polyclonal spheroids.  More work is needed to optimise the method to improve 
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1.  INTRODUCTION 
 
 
Glioma is the most common form of primary brain tumour, accounting for 
approximately 80% of all malignant central nervous system (CNS) tumours 
(Agnihotri et al., 2012).  Gliomas histologically resemble types of glial cells, such 
as astrocytes and oligodendrocytes, and are classified (according to the 2007 
WHO classification, Louis et al., 2007) based on their presumed cell of origin, such 
as astrocytomas, oligodendrogliomas and oligoastrocytomas.  The tumours are 
then further classified into four histopathological grades, based on the degree of 
malignancy, which provide information on prognosis and are characterised by 
features associated with proliferation, angiogenesis and necrosis (Louis et al., 
2007; Vitucci et al., 2011). 
 
Glioblastoma (GBM), a grade IV astrocytoma, is the most common and most 
aggressive glioma (Ostrom et al., 2013).  There is currently no cure; GBM patients 
have a poor prognosis with a median survival of just 4.6 months, increasing to only 
14.6 months upon therapy (Stupp et al., 2005).  The current treatment involves 
surgery to remove the bulk of the tumour, followed by concomitant radiotherapy 
and chemotherapy with the alkylating agent temozolomide (TMZ).  The location 
and extensive diffusion of the tumour throughout the brain often means it is 
impossible to remove the tumour entirely without causing damage (Mrugala, 
2013), while the blood-brain barrier hinders drug delivery to the site of tumour, with 
only low concentrations being found around the tumour of even effective drugs 
(Portnow et al., 2009).  Tumour recurrence consistently occurs, along with the 
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development of therapy resistance (Omuro et al., 2007).  Thus, a better 
understanding of GBM is needed in order to improve the management and 
treatment of the disease. 
 
Many high dimensional profiling studies have been conducted to further 
understand tumourigenesis in GBM (TCGA, 2008; Parsons et al., 2008).  The 
Cancer Genome Atlas (TCGA) research network underwent a study to 
characterise the genome alterations in GBM (TCGA, 2008).  They analysed DNA 
copy number, gene expression and DNA methylation aberrations in 206 GBM 
samples, plus nucleotide sequence aberrations in 601 genes from 91 samples 
using Sanger sequencing and microarray technology.  The results revealed 
numerous novel mutations and genome aberrations, as well as confirming 
previously known mutations.  Mapping of the genetic alterations onto major 
signalling pathways implicated in GBM, namely the p53, RB and receptor tyrosine 
kinase (RTK) pathways (Furnari et al., 2007) (Fig. 1), showed that 87%, 78% and 
88% of the GBM samples harboured genetic alterations in these pathways, 
respectively.  Indeed, the majority of the samples (74%) possessed genetic 
alterations in all three pathways (TCGA, 2008), helping the tumour cell to promote 
proliferation and survival, while escaping cell-cycle checkpoints, senescence and 
apoptosis (Chen et al., 2012).  These results suggest that deregulation of the three 
pathways is an essential requirement for GBM pathogenesis (TCGA, 2008). 
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Figure 1 – Major signalling pathways in GBM tumourigenesis 
Illustration of the key signalling pathways – the RTK, p53, and Rb pathways - that 
are mutated in GBM pathogenesis.  Oncogenes are highlighted in red, while blue 
indicates tumour suppressor genes (Chen et al., 2012). 
 
 
Although there are some conserved aberrations in GBM, there is great variability 
in biological behaviour between different tumours, with differences in prognosis 
and response to treatment commonly seen despite tumours sharing the same 
WHO histopathological grade (Vitucci et al., 2011).  There are two main categories 
of GBM: primary and secondary (Louis et al., 2007).  Primary GBM accounts for 
around 95% of all GBM cases and mainly occurs in older patients, with a mean of 
62 years old (Ohgaki et al., 2004).  These tumours arise de novo, resulting from 
the accumulation of multiple genetic aberrations.  Secondary GBM, on the other 
hand, has a median patient age of 45 years old and develops over 5-10 years from 
low-grade astrocytoma (Ohgaki and Kleihues, 2007).  These categories are 
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morphologically and clinically indistinguishable, but genome-wide analyses have 
shown there are marked genomic differences between primary and secondary 
GBM (Maher et al., 2006), suggesting that different types of treatment may be 
needed for each. 
 
As well as differences between tumours, significant intratumoural heterogeneity 
has been found (Zheng et al., 2012).  Gene expression profiling studies have 
revealed differences between samples from different regions of the same tumour, 
which are unrelated to differences in histology (Liang et al., 2005).  Furthermore, 
DNA copy number analysis of various samples taken from one tumour showed 
that GBM tumours have genetic alterations that are common to all areas of the 
tumour, as well as some that are area-specific (Nobusawa et al., 2010). 
 
Several studies have used gene expression profiling to classify histologically-
indistinguishable GBM tumour samples into specific subtypes (Huse et al., 2011; 
Dunn et al., 2012).  Initial profiling studies identified subclasses of GBM by 
analysing gene expression signatures associated with prognosis/survival or 
response to therapy (Nutt et al., 2003; Freije et al., 2004; Phillips et al., 2006).  
Phillips et al. (2006) used 107 grade III and grade IV astrocytoma samples, 
separating them into groups of short and long survival.  Microarrays were used to 
profile the gene expression in the two groups and two-way cluster analysis 
performed with the genes whose expression most strongly correlated with survival.  
Three subclasses were identified, characterised by a 35-gene signature, named 
Proneural, Proliferative or Mesenchymal, based on the expression of genes 
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characteristic of the corresponding tissues (Phillips et al., 2006).  Similar groups 
were also found by Freije et al. (2004), who looked at survival-associated 
transcription in 85 diffuse gliomas of all types.  The Proneural subtype was the 
least aggressive and had the best outcome, while the Proliferative and 
Mesenchymal subtypes had a worse outcome and had higher expression of 
markers for proliferation and angiogenesis (Freije et al., 2004; Phillips et al., 2006). 
 
More recently, gene expression profiling studies were used to identify GBM 
subtypes with transcriptional signatures associated with alterations in DNA 
sequence and copy number (Verhaak et al., 2010).  Verhaak et al. (2010) 
analysed the TCGA microarray gene expression data (thus only GBMs were 
included), isolated the variably expressed genes (totalling at 1740, not specifically 
related to survival) and performed unsupervised hierarchical clustering.  This 
resulted in four significantly different subtypes, with a 210-characteristic gene 
signature per class, named (following the previously established subtype titles) 
Classical, Mesenchymal, Proneural and Neural.  These subtypes were validated 
using an independent data set of 260 GBM samples (including those analysed by 
Phillips et al.) and gene expression data obtained from a collection of xenografts 
(patient specimens implanted in null mice, Hodgson et al., 2009).  The patterns of 
the four subtypes were well recapitulated by the validation data set, while 
Proneural, Classical and Mesenchymal subtypes were also reflected in the 
xenografts (Verhaak et al., 2010), supporting the use of this subclassification in 
GBM. 
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The four subtypes can be characterised by specific genomic events (Verhaak et 
al., 2010; Huse et al., 2011; Omuro and DeAngelis, 2013) (Fig. 2, Table 1).  The 
Classical subtype is characterised by EGFR amplification, which was observed in 
97% of the Classical samples while infrequently in other subtypes, as well as a 
point (or vIII) EGFR mutation leading to constitutive receptor activation.  CDKN2A 
(INK4A/ARF) deletion is frequently present, although there is a lack of TP53 
mutations in the Classical subtype, despite it being the most commonly mutated 
gene in GBM (TCGA, 2008).  The Mesenchymal subtype is associated with NF1 
mutation/deletion and high expression of mesenchymal markers, such as CHI3L1 
and MET, and genes involved in the tumour necrosis factor and NF-κB pathways.  
The Proneural subtype is enriched for mutations in IDH1 and TP53 (as well as 
TP53 loss of heterozygosity), plus amplification of PDGFRA.  Finally, the Neural 
subtype shows high expression of neuronal markers, but has no distinct 
aberrations from the other classes. 
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Figure 2 – Genomic alterations in different GBM subtypes 
Diagram showing the data for gene expression, mutations and copy number 
changes for 116 GBM samples, organised into the four subtypes.  Gene 
expression (ge) data was standardised (mean equal to zero, standard deviation 
equal to 1) and levels illustrated, with green for low expression and red for high 
expression.  Mutations (mut) are indicated by a red square (EGFRvIII is 
specifically shown by a yellow square) and loss of heterozygosity by a white line.  
Copy number changes (cn) are indicated with bright red for high level 
amplification, dark red for low level amplification, dark green for hemizygous 
deletions and bright green for homozygous deletions.  Black shows no alterations 

























TP53 20 (54%) 4 (21%) 0 (0%) 12 (32%) 36 
PTEN 6 (16%) 4 (21%) 5 (23%) 12 (32%) 27 
NF1 2 (5%) 3 (16%) 1 (5%) 14 (37%) 20 
EGFR 6 (16%) 5 (26%) 7 (32%) 2 (5%) 20 
IDH1 11 (30%)* 1 (5%) 0 (0%) 0 (0%) 12 
PIK3R1 7 (19%) 2 (11%) 1 (5%) 0 (0%) 10 
RB1 1 (3%) 1 (5%) 0 (0%) 5 (13%) 7 
ERBB2 2 (5%) 3 (16%) 1 (5%) 1 (3%) 7 
EGFRvIII 1 (3%) 0 (0%) 5 (23%) 1 (3%) 7 
PIK3CA 3 (8%) 1 (5%) 1 (5%) 1 (3%) 6 
PDGFRA 4 (11%) 0 (0%) 0 (0%) 0 (0%) 4 
 
Table 1 – Frequency of aberrations in frequently-mutated genes between the 
different GBM subtypes 
The number of samples in which alterations in each gene were detected within the 
Verhaak et al., dataset is shown.  The significance of the frequency of each event 
in each subtype compared to the remaining subtypes was determined (two-sided 
Fisher’s test) and significant aberrations indicated using bold (p<0.1) and an 
asterisk (p<0.01) (Verhaak et al., 2010). 
 
 
However, mRNA levels do not always correlate with protein levels.  Thus, Brennan 
et al. (2009) performed proteomic analysis on 27 surgical glioma samples.  Using 
unsupervised clustering, they found three distinct subtypes based on the pattern of 
activation of glioma-associated signalling pathways, each associated with EGFR 
activation, PDGFRA activation, or loss of NF1 (Brennan et al., 2009).  These 
classes correspond well with the Classical, Proneural and Mesenchymal 
subclasses of GBM determined using TCGA data, in which aberrations of EGFR, 
PDGFRA and NF1 are signature events, respectively (Verhaak et al., 2010). 
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Across several studies, the number of GBM subtypes varies between 2 and 4, with 
no consensus as of yet.  Part of the reason for this is likely due to lack of 
consistency in samples sets and methodology (Zheng et al., 2012).  Re-analysis of 
both the Phillips et al. and Verhaak et al. samples using the other’s subtype 
signatures revealed good agreement between the Mesenchymal and Proneural 
subtypes.  However, there was little concordance between the other subtypes.  
One reason for this may be that while the Proneural and Mesenchymal signatures 
in the Phillips et al. study were mostly mutually exclusive, elements of the 
Proliferative signature were often found in the other signatures and so may not 
have been defined as a subtype using the Verhaak method (Huse et al., 2011). 
 
The classification of GBM into subtypes has been linked to differences in survival 
(Phillips et al., 2004) and treatment efficacy (Verhaak et al., 2010).  Comparison of 
data from patients undergoing intensive radio-/chemotherapy compared to those 
undergoing noncurrent or short chemotherapy treatments showed that aggressive 
therapy significantly reduced mortality in the Verhaak Classical and Mesenchymal 
subtypes, with some effect in Neural subtypes too, but there was no change in 
survival in the Proneural subtype (the subtype which also correlated with longer 
patient survival) (Verhaak et al., 2010) (Fig. 3).  This suggests different subtypes 
may require different therapies.  Thus, studies have been done to try and improve 
diagnosis of GBM to be able to identify the subtypes present and so give improved 
prognosis and, potentially, personalised treatment.  One such study led to the 
development of an immunohistochemical method to look for expression of EGFR, 
p53 and PDGFR to allow classification into Classical (high EGFR, low 
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p53/PDGFR) or Proneural subtypes (high p53 and/or high PDGFR), showing the 
potential to be able to classify GBM with a simple method in daily practice (Le 




Figure 3 – Different responses are shown by the four GBM subtypes to 
conventional therapy 
Patients within a dataset were classified based on the therapy given – a red line 
indicates intensive therapy (including concurrent radio- and chemotherapy or 
extended chemotherapy) and a black line represents less intensive therapy (non-
concurrent radio- and chemotherapy or less than four cycles of chemotherapy).  
Patient survival (expressed as a ratio, starting at 1 before treatment) was plotted 
against time for each GBM subtype (Verhaak et al., 2010). 
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Several GBM cell lines have been established, some of which can be used to 
represent the distinct Verhaak subtypes Classical, Mesenchymal and Proneural, 
such as U343, U373 and U87 respectively.  Each possesses the characteristic 
genomic aberration of the corresponding subtypes (namely, changes in EGFR, 
IDH1 or NF1 [Table 1, Table 2]).  However, certain genetic alterations are lost in 
culture, including EGFR amplification (Schulte et al., 2012) and IDH1 mutation 
(Piaskowski et al., 2011).  Although the cause is still debated, the observation that 
the genotype of cells cultured in xenografts, 3D culture or serum-free conditions 
more closely reflects that of the primary tumours suggests that these cell types 
could have stem cell-like properties and so are lost during normal cell culture (Lee 
et al., 2006; De Witt Hamer et al., 2008).  Therefore, U87 has been engineered to 
contain a vector that expresses the IDH1 mutant (R132H) and so is not lost as it is 
not integrated into the genome, whereas U343 instead contains a mutation to give 
overexpression of EGFR, rather than amplification of the gene.  These cell lines 
have greatly aided the investigation to further understand GBM.  
 




EGFR High expression WT WT 
NF1 WT Low/deletion WT 
IDH1 WT WT 
Heterozygous 
mutant (R132H) 







PDGFRA WT WT Amplification 
Table 2 – GBM tumour cell lines possess aberrations characteristic of the 
different GBM subtypes 
(Ishii et al., 1999; Hollinshead, personal communication) 
 
 12  
 
Cellular spheroids are large clusters formed by spontaneous aggregation of cells 
and were among the first 3D cell culture models discovered and applied in 
research, often acting as tumour models (Hirschhaeuser et al., 2010; Pampaloni et 
al., 2013).  They provide an intermediate between 2D monolayers and in vivo 
tumours.  They have more complexity than monolayers and are more 
representative of tumours by better recreating cell-cell interactions and displaying 
areas of heterogeneity with, for example, proliferative cells focused on the edges 
of the spheroid, areas of necrosis and the presence of nutrient/oxygen gradients 
throughout to view hypoxic effects (Sutherland, 1998; Loessner et al., 2013).  They 
are often used in drug development studies, displaying more resistance to drugs 
than 2D monolayers (Elliot and Yuan, 2011) and allowing the drug response to be 
modelled with relevant pathophysiological gradients/microenvironments, including 
hypoxia, which is associated with tumour aggressiveness and resistance to 
therapy in vivo (Amberger-Murphy, 2009)).  Spheroids have also been shown to 
be more representative of GBM, specifically.  Genomic profiling of primary cell and 
spheroid cultures from GBMs showed substantial genetic changes in 2D cell 
culture compared to the parental tumours, whereas spheroid cultures were 
genetically stable and retained characteristic aberrations, such as EGFR 
amplification (De Witt Hamer et al., 2008), suggesting spheroid culture allows a 
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1.1  Hypothesis and Aims 
Previous work has shown that the three GBM cell lines, U373, U343 and U87, can 
be cultured as 3D spheroids.  The hypothesis of the present study was that 
spheroid cultures could be used as a more representative model of GBM tumours, 
using U373, U343 and U87 to represent intratumoural heterogeneity.  The model 
could lead to a better understanding of the spatial arrangement of the three 
subtypes in a GBM tumour and their cellular interactions.  Previous studies have 
also revealed differential sensitivity to conventional therapy between the subtypes.  
Thus, a further hypothesis was that a spheroid model of GBM could provide 
insights into the mechanism of preferential action of the drug TMZ between GBM 
subtypes in vivo.  The aims were, therefore, to: 
1. Develop a spheroidal model of GBM using fluorescently labelled U373, 
U343 and U87 to allow imaging by confocal microscopy 
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2.  MATERIALS AND METHODS 
 
 
2.1  Cell and Spheroid Culture 
GBM cell lines (Table 2) were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 2 mM L-glutamine and 10% (v/v) foetal calf serum 
(FCS), and incubated at 37°C C and 5% CO2 in a humidified environment until 
confluent.  For cell passaging, the medium was removed, before the cells were 
washed in PBS and incubated with trypsin solution (Gibco, Life Technologies) until 
all cells had detached from the dish.  DMEM was then added to neutralise the 
trypsin and the cells re-plated at the appropriate density. 
 
For spheroid culture, cells were seeded at a cell count of 1x106 in 10 ml medium 
onto 0.5% (w/v) low melting point (LMP) agarose plates to prevent the cells 
adhering to the plastic dish.  The plates were incubated at 37°C for 3 days, before 
the spheroids were harvested.  The spheroids were collected on a 40 µm filter, the 
filter washed with PBS and the spheroids transferred to an Eppendorf tube.  The 
samples were centrifuged (8000 rpm, 1 min) to pellet the spheroids, the liquid 
removed and the spheroids fixed by incubating at room temperature (RT) with 
10% formalin for 1 hour. 
 
Where appropriate, on the third day of growth on agarose plates, spheroids were 
treated with 1 mM TMZ, dissolved in DMSO, (plus a control plate treated with an 
equal volume of DMSO) and incubated for a further 3 days before harvesting. 
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2.2  TMZ-Sensitivity Assay 
Each cell line was seeded onto 12-well plates at a cell density appropriate for rate 
of growth: U87 at 0.3x105, U343 at 0.4x105 and U373 at 0.1x105 cells per well.  
The plates were incubated overnight at 37°C.  The medium was aspirated and 
fresh medium added containing various concentrations of TMZ ranging 0 – 1 mM 
(with 3 wells for each concentration).  For each TMZ plate, a control plate was 
used in which the equal volume of DMSO was added to account for any cell death 
due to DMSO alone.  The plates were incubated at 37°C for 72 hours, before the 
cells were fixed by incubation for 30 mins at 4°C with 200 µl of 20% (w/v) 
trichloroacetic acid (TCA) per well.  The plates were washed with water, allowed to 
dry and 0.4% (w/v) sulforhodamine B (SRB) in 1% (v/v) acetic acid added for 10 
mins at RT to stain the cells.  The plates were washed four times with 1% (v/v) 
acetic acid to remove any unbound dye and allowed to dry.  The protein-bound 
dye was dissolved in 50 mM Tris solution (pH 8.8) and the absorbance at 510 nm 
measured using a microplate reader (FLUOstar Omega, BMG Labtech) with the 
absorbance proportional to cell number.  TMZ cytotoxicity was calculated by 
dividing the absorbance of the non-treated cells by that of the TMZ-treated cells 
and normalising the value to that of the corresponding DMSO-treated plate. 
 
2.3  Western Blotting 
For 2D cell culture, the medium was removed from the plate and the cells washed 
three times in PBS.  The cells were then harvested by scraping in ~500 µl RIPA 
buffer (plus protease inhibitors).  For spheroid culture, cell spheroids were 
collected from the agarose plates and centrifuged (2000 rpm, 5 mins) to pellet the 
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cells.  The supernatant was removed and the cells were washed with PBS, before 
the pellet was resuspended in ~150 µl RIPA buffer (with protease inhibitors). 
 
Samples were incubated on ice for 20 minutes to lyse the cells and centrifuged at 
13000 rpm for 15 mins at 4°C.  The supernatant was retained and the protein 
concentration measured using a BCA protein assay (Thermo Scientific).  Samples 
were diluted to give equal concentrations and added to an equal volume of 2x 
Laemmli sample buffer (Sigma-Aldrich), before boiling at 100°C for 10 mins to 
denature the proteins. 
 
The proteins were separated using sodium dodecyl sulphate-polyacrylaminde gel 
electrophoresis (SDS-PAGE) and subsequently transferred to a nitrocellulose 
membrane using a wet-transfer method.  The membranes were incubated with 5% 
(w/v) milk in PBST (0.1% (v/v) Tween 20 in 1x PBS) for 1 hour to block the 
membranes, before being incubated with the primary antibody (made to the 
correct dilution in 5% milk) (Table 3) and left on a rocker overnight at 4°C.  The 
blots were washed in PBST to remove any unbound antibody and incubated with 
secondary antibody, mouse- or rabbit-IgG reactive HRP-linked antibody (cell 
signalling), for 1 hour on a shaker.  Blots were then washed with PBST for 3x10 
mins to remove unbound secondary antibody. Enhanced chemiluminescent (ECL) 
reagent (GE Healthcare) was added to the membrane to allow detection of the 
protein.  The blots were exposed to x-ray film for the appropriate time and the film 
was developed. 
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2.4  Immunofluorescence 
Spheroids were harvested and fixed, before centrifugation (8000 rpm, 1 min) to 
pellet the spheroids, the supernatant removed and the cells permeablised with 
0.1% (v/v) Triton-X-100 in PBS for 20 mins.  The samples were again centrifuged 
(8000 rpm, 1 min) and the spheroids incubated in 5% (w/v) BSA for 1 hour at RT.  
The BSA was removed and the samples incubated at 4°C overnight with 500 µl 
primary antibody (Table 3) in 1% (w/v) BSA on a spinner. 
 
The spheroids were washed with PBS, centrifuged (8000 rpm, 1 min) and the 
supernatant removed.  Secondary antibody, conjugated to a fluorescent dye 
(Dylight 649 Anti-rabbit/mouse-IgG, Vector Labs), was added in 250 µl PBS and 
incubated in the dark for 2 hours.  The antibody was removed and the wash 
repeated.  500 µl PBS was added, along with a drop of Hoescht dye 
(Hoescht33342, Life Technologies) to stain the nuclei.  The spheroids were added 
to chamber slides and 200 µl 1% (w/v) LMP agarose added to the top of the well to 









β-actin 1:2000 - Mouse Sigma-
Aldrich 
EGFR 1:500 1:50 Rabbit Santa Cruz 
EGFR - 1:50 Rabbit Cell 
Signalling 
HIF1α - 1:50 Mouse BD 
Biosciences 
IDH1 R132H 1:500 - Mouse Dianova 
NF1 1:500 - Rabbit Abcam 
Table 3 – Primary Antibodies 
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2.5  Confocal Microscopy 
Samples were imaged using a Zeiss LSM 510 confocal microscope, connected to 
an inverted Axiovert 200M microscope.  The objective lens used was an EC Plan – 
Neofluar 20x with a numerical aperture of 0.5.  Images were processed using the 
Zeiss LSM Image Browser software. 
 
2.6  Spheroid Size Measurements 
Spheroids were imaged on the agarose plates using a Zeiss Axiovert 25 inverted 
light microscope and subsequently captured and processed using the Scion 
VisiCapture software.  The area of each spheroid was measured using ImageJ 
software and the value used to calculate the average radius of the spheroid 
according to      .  The volume was then approximated, assuming a sphere 
shape, using   
 
 
   .   
 
2.7  FACS 
Cells were grown in a monolayer until confluent.  The medium was removed, the 
plate washed with PBS and the cells trypsinised.  The trypsin was neutralised with 
the addition of medium and the cell solution centrifuged (1500 rpm, 5 mins).  The 
supernatant was aspirated and the pellet resuspended in 1 ml PBS with 
gentamycin.  The cells were passed through a 70 µm filter to remove any 
contaminants and subsequently sorted using FACS.  The sorted cells were plated 
with antibiotic-containing medium to prevent infection following the FACS 
procedure. 
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3.  RESULTS 
 
3.1  GBM Cell Lines Can be Classified into Distinct GBM Subtypes 
The aim of the present study was to use GBM-derived cell lines to develop a 
model of a GBM tumour.  In order to confirm the supposed genetic alterations of 
the three cell lines, U87, U343 and U373, a Western blot was performed to 
analyse the relative levels of the NF1, EGFR and IDH1 (R132H) proteins in each 
cell type (Fig. 3). 
 
Figure 3 – Expression of key protein markers for GBM subtypes in the cell 
lines U87, U343 and U373 
Cells were grown as a monolayer until confluent, harvested by scraping and lysed.  
The protein concentrations in each sample were measured and a Western Blot 
performed to observe the relative levels of EGFR, NF1 and IDH1 with the R132H 
mutation.  β-actin was used as a loading control. 
 
 
The results revealed that U87 cells solely expressed the IDH1 mutant protein, 
while possessing normal levels of both EGFR and NF1, whereas U373 cells 
displayed no/low NF1 protein levels, with no other aberrations detected.  This 
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suggests that the U87 and U373 cell lines can be used to represent the Proneural 
and Mesenchymal GBM subtypes, respectively.  U343 cells, however, also 
showed only low levels of NF1 (at levels similar to those in U373).  Nonetheless, 
EGFR could only be detected in U343 cells, indicating the EGFR gene is indeed 
overexpressed in this cell line, which is a marker of the Classical subtype and 
thus, allowed the U343 cell line to be used to represent the Classical phenotype.   
 
3.2  Sensitivity to TMZ Treatment Differs for Each Subtype In Vitro  
Previous studies have suggested that each GBM subtype has a different response 
to conventional therapy (radiotherapy with concomitant TMZ chemotherapy) in 
patients (Verhaak et al., 2010).  The effects of TMZ treatment on each cell type 
grown as a 2D monolayer were analysed using a cell viability/SRB assay to 
monitor cell numbers at varying concentrations of TMZ.  The results were 
normalised to a DMSO-treated control plate (as the TMZ drug is dissolved in 
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Figure 4 – Varying sensitivity of U87, U343 and U373 to TMZ treatment 
Cells grown in a monolayer were treated with varying concentrations of TMZ and 
incubated for 72 hours.  The cells were fixed and an SRB assay performed to 
measure cell viability.  The results were normalised to cell count when no TMZ 
was added and are shown relative to the results from the treatment of an equal 
volume of DMSO.  N=3, error bars indicate standard error of the mean. 
 
 
The findings show varying levels of sensitivity to TMZ between the three cell types.  
U373/Mesenchymal cells were the most responsive to TMZ treatment, with 
U343/Classical cells also showing substantial cell death upon TMZ treatment.  
U87/Proneural cells were the most resistant to TMZ therapy.  This indicates that 
each cell line possesses distinct characteristics and that TMZ has different 
efficacies per GBM subtype in vitro. 
 
 
S e n s it iv ity  o f  G B M  C e ll  L in e s  to  T M Z
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3.3  GBM Cell Lines Can Form Monoclonal Spheroids 
Spheroids have been shown to be more representative of GBM tumours than 2D 
monolayer culture (De Witt Hamer et al., 2008).  GBM cell lines engineered to 
endogenously express a fluorescent protein – U87-GFP, U343-YFP, and U373-
RFP – were seeded onto agarose plates and cultured for three days to form 
spheroids.  Following incubation with Hoescht stain (to label the nuclei) and 
immunofluorescent labelling of HIF1α, a protein marker of hypoxia, the spheroids 
were imaged using confocal microscopy (Fig. 5). 
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Figure 5 – GBM cell lines can be cultured as spheroids 
U343-YFP (A), U87-GFP (B) or U373-RFP (C) cells were seeded onto individual 
agarose plates to form spheroids, then harvested and fixed after three days 
growth.  The spheroids were permeablised and incubated with an antibody against 
HIF1α, followed by incubation with a secondary antibody tagged with a far-red dye 
(Dylight649), to indicate hypoxic regions.  Hoescht stain was also added to label 
the nuclei.  The spheroids were imaged using confocal microscopy at wavelengths 
appropriate for Hoescht (top left of each picture), the endogenous fluorescent 
protein (top right) and HIF1α-Dylight649 (bottom left), with the collective image 
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The results show that each of the cell lines can spontaneously form multicellular 
spheroid structures.  The Hoescht stain only labelled cells on the periphery of the 
spheroid.  Replacement of Hoescht stain (a live cell stain) with DAPI (a fixed cell 
stain) showed no change in the coverage of the dye.  It is possible that the solution 
could not penetrate into the centre of the spheroid.  The endogenous fluorescence 
indicates cells are present throughout the spheroid in both U343 and U373 
cultures, suggesting they form solid, tightly-packed structures.  The GFP 
fluorescence of the U87 cells, however, is mainly focussed around the edges of 
the spheroid, with the centre showing a dimmer fluorescence that also has a less 
cellular appearance with fewer distinct shapes, suggesting the U87 spheroids are 
not solid.  Immunofluorescence to see the localisation of HIF1α revealed a hypoxic 
environment in the core of each spheroid.  Indeed, a distinction can be seen 
between the position of the outer cells, stained with Hoescht, and where the HIF1α 
far-red staining begins within the spheroid.  The presence of oxygen 
gradients/hypoxia is consistent with previous studies that suggest spheroids are 
more representative of tumours than 2D cell culture and are, therefore, a better 
model to use in understanding GBM tumours.  Interestingly, the HIF1α staining in 
the U87 spheroids is different, displaying more distinct spots of fluorescence 
compared to diffuse staining with the other two cell lines.  The staining could be an 
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3.4  Confocal Imaging Can be Improved Using Cells Sorted by FACS 
The previous images showed a poor fluorescent signal of the endogenous GFP in 
U87 cells, while only a small proportion of the U373 cells displayed a strong RFP 
signal.  Therefore, these cell lines underwent a FACS procedure to select those 
cells with the strongest fluorescent signal.  Confocal imaging of the sorted U87-
GFP cells (Fig. 6) showed a substantial improvement in the GFP fluorescence and 
the images obtained.  However, due to contamination during the FACS procedure, 
the U373-RFP cells were unable to be sorted and re-cultured, and the U87-GFP 
cells were eventually also lost to infection.  Nevertheless, the images obtained 
show the benefits that sorting the fluorescently-labelled cells by FACS can bring to 



















Figure 6 – Sorting of U87-GFP cells using FACS improves confocal imaging 
U87-GFP cells were sorted using a FACS protocol to select those with the highest 
fluorescent signal, before culturing as spheroids.  The spheroids were harvested 
on day 3 of growth, stained with Hoescht, and the HIF1α protein 
immunofluorescently labelled with a far-red dye, Dylight649.  The spheroids were 
subsequently imaged using confocal microscopy, taking a z-section within the 
centre of the spheroid, to detect the Hoescht (top left), endogenous GFP (top right) 
and HIF1α-Dylight649 fluorescent signals (bottom left). 
GFP Hoescht 
HIF1α-Dylight649 All 
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3.5  The Effects of TMZ Treatment on Monoclonal Spheroids 
To investigate the effect of chemotherapy on the cell lines in spheroid culture, 
monoclonal spheroids were treated with TMZ and imaged, along with a control 
DMSO-treated sample (Fig. 7).  As confocal microscopy allows imaging of only a 
small number of spheroids, along with the added bias of selecting those of a 
suitable size or strong fluorescence, an overall range of the sizes of the spheroids 
in each sample was obtained to allow comparison between cell lines and 
conditions (Fig. 8). 
 
The U343-YFP spheroids (Fig. 7a) showed no change in phenotype, as well as no 
significant change in volume.  However, both the U373-RFP and U87-GFP 
spheroids displayed a change in morphology following TMZ treatment.  The U373 
spheroids (Fig. 7b) had decreased endogenous and immunofluorescent staining in 
the spheroid centre, suggesting they may become hollow with treatment.  Despite 
this change in morphology, there was no overall change in size, suggesting low 
TMZ efficacy.  On the other hand, the U87 spheroids (Fig. 7c) demonstrated an 
increase in spheroid cell density and a smaller necrotic core, with higher 
endogenous and HIF1α fluorescence towards the centre of the spheroid.  There 
was also a change in volume.  The TMZ-treated spheroids formed two 
populations, some that were indeed smaller than the control samples, indicating 
cell killing, but some significantly larger.  The smaller necrotic core could allow the 
formation of larger, more stable spheroids.  Thus, the three different GBM 
subtypes respond differently to chemotherapy. 
 


















Figure 7 – Response of spheroid cultures to TMZ treatment 
U343-YFP (A), U373-RFP (B) and U87-GFP (C) spheroids were cultured for 3 
days, before treating with 1 mM TMZ (or an equal volume of DMSO) and 
incubating for a further 3 days.  Spheroids were harvested, fixed and 
permeablised, and HIF1α immunofluorescently labelled with Dylight349 and the 
nuclei stained with Hoescht.  Confocal microscopy was used to image the 
samples, taking a z-stack from near the centre of the spheroid, using wavelengths 
suitable to detect the fluorescence of Hoescht, endogenous fluorescent protein 
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Figure 8 – The effect of TMZ treatment on spheroid size 
(A) U343 spheroids were treated with 1 mM TMZ for 72 hours, or an equal volume 
of DMSO as a control.  The resulting spheroids were imaged using an inverted 
light microscope and the images subsequently analysed using Image J software to 
estimate the spheroid volume (assuming a sphere shape).  The mean is shown by 
the black line and the error bars represent the standard deviation.  * – significant at 
p<0.05, calculated using an unpaired t test; ns – non-significant at p<0.05. (N=2) 
(B) and (C) As for (A) but using U373 and U87 spheroids, respectively. 
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3.6  GBM Subtypes Have a Distinct Arrangement Within a Polyclonal Spheroid 
Next, U343-YFP, U373-RFP and U87-GFP cells were cultured together to form 
polyclonal spheroids.  However, upon imaging, the GFP and YFP signals could not 
be distinguished due to the overlap between their emission spectra (Fig. 9a). 
 
To allow the different colours in a polyclonal spheroid to be differentiated during 
confocal microscopy, ‘unmixing’ software was used.  Spectra were first obtained 
for each of the fluorescent colours separately.  Then, upon imaging of the 
polyclonal spheroids, the LSM unmixing software was used, with which the 
individual spectra were applied to the spheroid to separate and identify the various 
emission wavelengths (Fig. 9b).  
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Figure 9 – Arrangement of cell types in a polyclonal spheroid 
(A) U87-GFP, U343-YFP and U373-RFP cells were cultured together for 3 days to 
form spheroids.  The spheroids were harvested, fixed and permeablised, before 
immunofluorescently labelled with far-red Dylight649 against the HIF1α protein.  
They were then imaged by confocal microscopy, with the resulting image shown.  
(B) The polyclonal spheroid images (A) were processed using LSM unmixing 
software to allow the different fluorescent colours to be distinguished from one 
another.  The image of each individual fluorescent signal is shown (as labelled) as 
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The results reveal that, rather than the different cell types displaying a random 
distribution throughout the spheroid, they instead form distinct populations.  The 
U343-YFP cells were consistently found to pack tightly together through the centre 
of the spheroid, while the U87-GFP cells were found focussed at the periphery of 
the spheroid (in line with that seen in the U87 monoclonal spheroids).  However, 
there still appears to be some overlap between these two signals.  It was difficult 
to image the U373-RFP cells in the polyclonal spheroids due to their low intensity 
fluorescence, but upon dramatically increasing the RFP brightness in various 
samples, the results suggest they are more diffuse through the spheroid, with 
more variable positions. Thus, it may be the U343 and U87 cells that determine 
the structure and cell organisation of the spheroid. Furthermore, only low levels of 
HIF1α were seen in the polyclonal spheroids compared to the monoclonal 
spheroids, suggesting that the conditions within the spheroid core are not right for 
stabilisation of the HIF1α protein.  Therefore, it may be the different subtypes 
arrange in the most beneficial organisation to give the least cellular stress. 
 
3.7  The Impact of TMZ Treatment on Polyclonal Spheroids 
TMZ has been shown to affect the spheroids of the different cell lines in different 
ways.  To further investigate the effects of chemotherapy on GBM tumours, 
polyclonal spheroids were treated with TMZ for 72 hours, before viewing any 
changes in spheroid morphology using confocal imaging and analysing volume 
change (Fig. 10). 
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Figure 10 – The effect of TMZ on polyclonal spheroids 
(A) U343-YFP, U373-RFP and U87-GFP cells were incubated together for 3 days 
to form polyclonal spheroids, before treating with DMSO for a further 72 hours.  
Spheroids were harvested, fixed and permeablised, followed by 
immunofluorescent staining of HIF1α with a far-red Dylight649 fluorescent dye.  
The samples were imaged using confocal microscopy and processed using LSM 
unmixing software to separate between the different colours.  The images show: 
RFP - top right; GFP - top middle; Hoescht - top right; YFP - bottom left; 
Dylight649 - middle bottom, collective colours – bottom right.  (B) As for (A), 
except treating the spheroids with 1 mM TMZ.  (C) Polyclonal spheroids were 
treated with 1 mM TMZ or an equal volume of DMSO for 72 hours.  The spheroids 
were imaged using an inverted light microscope and analysed using Image J 
software to enable estimation of spheroid volume (assuming a sphere shape). 
 
 
The images show a change in cell organisation within the spheroid following TMZ 
treatment.  Generally, while there is little change in U87-GFP positions, there is a 
decrease of U343-YFP in the spheroid core.  This could be due to cell death 
leading to a larger necrotic core, or the U343-YFP cells moving towards the edges 
of the spheroid as they can no longer cope with the increased cellular stress, in 
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addition to the low nutrient and oxygen status in the spheroid centre.  Again, it is 
difficult to visualise the U373-RFP cells due to the poor fluorescent signal.  The 
analysis of spheroid volumes (Fig. 10C) revealed no significant change compared 
to DMSO-treated spheroids, showing that despite the change in phenotype, the 
drug has little overall effect on the spheroids. 
 
3.8  EGFR Immunofluorescence of U343/Classical Cells 
Spectral overlap between the YFP and GFP fluorescence of U343 and U87, 
respectively, was shown to be a problem in imaging polyclonal spheroids due to 
difficulties in distinguishing between the two colours.  Therefore, non-fluorescently 
labelled U343 could be used along with immunofluorescence staining of EGFR – 
the expression of which was shown to be only detectable in U343 cells (Fig. 3) – to 
instead label the U343 cells with Dylight649 far-red fluorescence and thus allow 
distinction between the three cell types in a single spheroid.  To confirm that 
EGFR immunofluorescence is suitable for imaging and allows good coverage 
throughout the spheroid, it was first used with U343 monoclonal spheroids.  To 
ensure there would be no cross-labelling of the other cell lines, the procedure was 
simultaneously performed with U87 and U373 monoclonal spheroids (Fig. 11). 
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Figure 11 – Immunofluorescence of U343 cells using an EGFR-reactive 
antibody shows cross-reactivity between the different strains. 
(A) U343 spheroids were harvested, fixed and immunofluorescence performed 
using an antibody specific for EGFR and a secondary antibody with a far-red tag 
(Dylight649) at 1:50 dilution.  The spheroids were imaged using confocal 
microscopy.  (B)  U343-YFP spheroids were harvested, fixed and stained with 
Hoescht before imaging with confocal microscopy.  (C,D) As for (A), except with 
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The results show that labelling the U343 cells with EGFR immunofluorescence 
allows good coverage of the spheroids and a strong fluorescent signal (as 
compared to that seen with endogenous YFP [Fig. 11b]).  However, staining of 
both the U87 and U373 spheroids was also observed, suggesting the EGFR 
antibody could also bind to these cell lines. 
 
Next, as the cross-reactivity may have been due to high antibody concentrations, 
the immunofluorescence was repeated on U343 spheroids using varying dilutions 
of primary antibody to identify the lowest concentration of antibody allowing 
staining of the spheroids (Fig. 12).  The confocal images still show strong 
fluorescence at 1:250 dilution, but there seems to be no further change at dilutions 
above 1:500.  Therefore, the immunofluorescence was repeated at 1:250 dilution 
of EGFR antibody with all cell lines and imaged using confocal microscopy.  Again, 
the Dylight659 fluorescence could be seen across all spheroid lines.  This result 
was also obtained using non-fluorescent protein expressing cell lines (Fig. 13), 
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Figure 12 – EGFR 
Immunofluorescence of U343 
spheroids with varying antibody 
dilutions 
U343 spheroids were harvested and 
fixed, before undergoing 
immunofluorescent staining with an 
EGFR primary antibody and a far-red 
fluorescently-tagged secondary 
antibody added at varying dilutions, as 
shown.  The samples were imaged 
using confocal microscopy with 
wavelength 633 nm (top right) (and 364 



















Figure 13 – EGFR 
immunofluorescence leads to 
staining of U343, U87 and U373 
non-fluorescent cell lines 
Spheroids were grown using cell lines 
not expressing a fluorescent protein: 
U343 (A), U87 (B) and U373 (C).  
After 3 days, the spheroids were fixed 
and incubated with an EGFR-reactive 
antibody, followed by a Dylight649-
tagged secondary antibody.  The 
samples were imaged using confocal 
microscopy to view the far red 
fluorescent signal (Dylight649, top 
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As it is possible that the expression of growth factor receptors is altered in 3D 
culture, a Western blot was performed using cells harvested from a spheroid 
culture and the levels of EGFR in each cell line measured (Fig. 14). 
 
 
Figure 14 – EGFR protein levels are maintained in spheroid culture 
U343, U87 and U373 monoclonal spheroids were cultured for 3 days, before 
harvesting, cell lysing and measuring the protein concentrations.  A Western blot 
was performed with the three samples and the levels of EGFR measured 




The Western blot shows that EGFR protein levels in spheroid culture are 
consistent with those from 2D monolayers, as EGFR can only be detected in U343 
cells.  Therefore, it was likely that antibody non-specificity was causing the staining 
to occur on all cell type spheroids.  The experiment was repeated using a different 
EGFR-reactive antibody (Fig. 15). 




Figure 15 – A new EGFR antibody still demonstrates cross-reactivity 
between cell lines 
(A) U343 cells were cultured for 3 days as spheroids, before fixing and 
permeablising.  EGFR (Cell Signalling primary antibody) immunofluorescence, 
using a far-red Dylight649-tagged secondary antibody, was then used to visualise 
the cells using confocal microscopy.  (B,C) As for (A), but using U373-RFP and 
U87-GFP cell lines, respectively. The images show the individual fluorescent 
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The images of the U343 immunofluorescence were promising, suggesting higher 
specificity as distinct cell outlines could be seen (as expected for reactivity to a cell 
surface receptor), but they also showed poor permeability of the antibody.  
Accordingly, no EGFR immunofluorescence was detected for the U373-RFP 
spheroids.  However, a strong far-red fluorescent signal was seen in the U87-GFP 
spheroids.  As Western blotting showed EGFR expression in U343 spheroids 
specifically, it suggests again the antibody is non-specific and cross-reacting with 
another molecule present on the surface U87, but not U373 cells.  Use of a third 
EGFR-reactive antibody led to immunofluorescence of all three cell lines once 
again.  Therefore, further optimisation would be required to use 
immunofluorescence to overcome the problem of GFP/YFP spectral overlap. 
 
 
In conclusion, spheroid culture of GBM cells lines provides a more representative 
model of a GBM tumour than 2D monolayers, as indicated by the presence of 
hypoxia and altered responses to therapy.  Polyclonal spheroids provided insight 
into the arrangement of the different GBM subtypes within a tumour, each showing 
preference for particular locations within the spheroid.  The distinct subtype 
organisation is also affected by TMZ treatment, highlighting a potential mechanism 
of TMZ action.  However, more work is required to obtain reliable images of the 
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4.  DISCUSSION 
 
 
The aim of the present study was to develop a new model of GBM using spheroid 
culture of different GBM cells lines, which can represent the different subtypes 
found in a GBM tumour.  This model was then used to analyse the interaction 
between the different subtypes and observe the effects of TMZ chemotherapy.  A 
Western blot was used to confirm the cell lines could be used to represent the 
specific subtypes by looking at the expression of the signature proteins EGFR, 
NF1 and IDH1 R132H (Fig. 3).  While the U87 and U373 cells lines were shown to 
be representative of Proneural and Mesenchymal subtypes, respectively, U343 
cells were shown to have both an NF1 deletion (characteristic of Mesenchymal) 
and EGFR overexpression (characteristic of Classical).  This challenges the 
reliability of the use of the U343 cells to represent the Classical subtype of GBM.  
Furthermore, the use of the expression of just three proteins to distinguish 
between the subtypes is an oversimplification.  A number of genetic alterations 
have been shown to be characteristic of the individual subtypes (Fig. 2) which 
could additionally be considered when selecting the most appropriate cell lines for 
this study.  Epigenetics is also well-known to influence the phenotype of cells and 
recently, that of GBM subtypes specifically.  G-CIMP methylation, for example, is 
correlated with the Proneural subtype and is involved in conferring a survival 
advantage (Brennan et al., 2013), therefore epigenetic status of the cell line can 
also influence how well their behaviour exemplifies the corresponding subtype.  
Clark et al., 2010, found limited similarity between the U87 cell line and primary 
GBM samples, while 2D culture has been shown to cause genetic changes from 
primary samples (De Witt Hamer et al., 2008).  This calls into question the use of 
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monolayer-cultured cell lines to develop a physiologically-relevant GBM model.  
Potentially, primary cell lines could be cultured as spheroids, providing a better 
representation of GBM and allowing the genetic modifications to be maintained. 
 
 
Imaging of the fluorescently-labelled GBM cell lines cultured as a polyclonal 
spheroid revealed a specific organisation of the different cell lines (Fig. 9).  U343-
YFP cells were consistently found to pack tightly in the spheroid core, while U373-
RFP spheroids seemed to be more diffuse through the spheroid.  U87-GFP cells, 
on the other hand, were concentrated around the edges of the spheroid.  These 
localisations are consistent with those seen for the monoclonal spheroids, in which 
U343-YFP and U373-RFP cells formed solid structures, but U87-GFP spheroids 
appeared more hollow.  This suggests that the cell lines each have preferences for 
the different conditions experienced throughout the spheroid.  U343-YFP cells 
seem to be highly resistant to hypoxia and nutrient deprivation and so are 
positioned in the spheroid core.  U373-RFP cells similarly seem to be resistant to 
such stress, but do not have a preference for position in the spheroid.  U87-GFP 
cells are typically located at the spheroid periphery.  IDH1 mutation has been 
linked to hypoxia in two conflicting theories.  The first suggests that mutation of 
IDH1 leads to lower levels of its catalytic product α-ketoglutarate, which normally 
promotes degradation of the HIF1α protein, thus leading to increased HIF1α in the 
cell and a ‘pseudohypoxic’ phenotype (Zhao et al., 2009).  The second theory 
states that the IDH1 mutant protein gains the ability to produce R-2-
hydroxyglutarate, which stimulates HIF1α degradation, therefore leading to lower 
HIF1α levels.  In support, the HIF signature was seen to be diminished in 
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Proneural tumours in the TCGA data (Koivunen et al., 2012).  This suggests that 
Proneural cells may not be able to adapt to hypoxic conditions, supporting the 
results of the present study and explaining their preference for the spheroid edges.  
Therefore, these results suggest that GBM subtypes form distinct populations 




However, the polyclonal spheroids in this experiment did not contain any Neural 
subtype cells.  Although such cell lines would be difficult to obtain due to the lack 
of defining genetic alterations, their presence may affect the cellular organisation 
within the tumour.  Moreover, despite using software to differentiate between the 
various emission spectra in the polyclonal spheroid, considerable overlap can still 
be seen between the GFP and YFP fluorescence.  This questions the reliability of 
the results seen here.  Therefore, the next steps in this study would be to reduce 
spectral overlap between the different cell lines.  Attempts to replace the YFP 
signals of the U343 cell line with far-red EGFR immunofluorescence were 
unsuccessful due to antibody non-specificity.  The use of one EGFR antibody (Fig. 
15) caused immunofluorescent staining of U343 cells, overexpressing EGFR, but 
not U373 cells, showing this method has potential.  However, staining could also 
be seen with U87 cells.  This suggests that the U87 cell line expresses a surface 
receptor, not present on the U373 cells, that possesses structural similarity to 
EGFR.  It is possible that this molecule is in the PDGFR family, the expression of 
which is known to be up-regulated in Proneural cells and is associated with stem-
like cells, explaining its expression in spheroid culture.  A microarray of the three 
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cell lines could be performed to determine the molecule causing the cross-
staining.  Another EGFR-specific antibody could be tested for use in this method.  
 
 
 However, the next step would be to re-engineer the cell lines to express a 
different coloured fluorescent tag – specifically change the U343-YFP label to 
endogenously express a protein with an emission spectra distant from that of GFP 
and RFP, e.g. BFP.  The U373-RFP fluorescence has also demonstrated a poor 
signal, making it difficult to visualise the cells, particularly in the polyclonal 
spheroid.  FACS could be repeated to select the cells expressing the RFP with the 
strongest fluorescence or the U373 cells could be engineered to express a 
different, possibly brighter, tag such as mCherry.  The consistent loss of 
endogenously expressed fluorescent protein from these cells has also been an 
issue.  The new transfections could therefore be performed using lentiviral vectors, 
which show high frequency transduction of dividing and non-dividing cells, 
resulting in stable/long-term integration into the genome (Naldini et al., 1996). 
 
 
The sensitivity of each of the cell lines to TMZ was investigated.  Spheroids have 
been shown to display a significant reduction in drug sensitivity compared to 2D 
culture (Durand and Olive, 2001).  Concordantly, both the U373 and U343 cell 
lines showed substantial cell death upon TMZ treatment in 2D culture (Fig. 4), but 
showed no significant change in spheroid volume in monoclonal 3D culture 
(despite some change in morphology in the U373 spheroids) (Fig. 7/8), suggesting 
increased resistance to therapy in spheroid culture.  The U87 cells exhibited a 
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change in morphology, with a smaller necrotic core, plus changes in volume size.  
Some spheroids appeared smaller, suggesting cell killing, while others were 
significantly larger than the control.  This indicates cells in a spheroid behave 
differently to a monolayer and are a better model to study drug efficacy.  The 
increased size of some spheroids could be due to the smaller necrotic core 
allowing the formation of larger, more stable structures.  It could also be that the 
cell size has increased, as the TMZ may affect cell division.  This could be further 
studied by increasing the magnification when imaging the treated cells, or using 
flow cytometry of disaggregated spheroids to measure differences in cell size or 
DNA content.  Polyclonal spheroids also displayed no significant change in 
volume, suggesting low treatment efficacy, but there was a change in morphology 
(Fig. 10), with a decrease in cells in the core perhaps due to killing of the cells 
already under increased cellular stress due to nutrient/oxygen deficiency. 
 
 
However, the current treatment given to patients involves concomitant chemo- and 
radiotherapy, while TMZ given as a single agent has limited benefits (Stupp et al., 
2001).  The next steps would therefore be to study the effects of both radiation and 
TMZ therapy on spheroid phenotype and size.  The results could then be 
compared to the treatment efficacy for each subtype from primary samples by 
Verhaak et al. (2010) to assess how representable the cell lines are of their 
corresponding GBM subtype.  Cell viability in the spheroids could also be analysed 
in the treated vs. control samples.  Immunofluorescent staining of proliferative (e.g. 
Ki67) and apoptotic (e.g. caspases) markers could be used (Loessner et al., 
2013), followed by confocal microscopy, to indicate cell viability in different regions 
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of the spheroid upon treatment.  Alternatively, the APH assay, based on levels of 
cytosolic acid phosphatase, could be used to indicate cytotoxicity in spheroid 
cultures (as described in Mikhail et al., 2013). 
 
 
The measurement of spheroid volumes highlighted the variability of sizes (and 
shapes) of the spheroids within each sample and between experiments.  This also 
added bias to the confocal microscopy, as only those spheroids of an appropriate 
size, fitting into the field of vision, were imaged.  Recently, new methods of 
spheroid growth have been developed, which allow the formation of spheroids with 
a uniform size and shape.  They involve using microwells, coated with non-
adherent substances, to restrict the spheroids to defined sizes, while microfluidics 
allow continued contact with growth medium (Hirschhauser et al., 2010).  Another 
method adapts the ‘hanging drop’ procedure of spheroid culture, in which cells are 
suspended in drops of medium.  The cells are confined by the diameter of the 
plateau on the bottom surface, giving consistent geometry, plus access holes in 
the hanging drop plate allow easy access, e.g. to change media or add drugs 
(Mehta et al., 2012).  These methods are both more high-throughput and would 
allow higher reproducibility between experiments for future work in this study. 
 
 
In conclusion, this study used a spheroid model to study the polyclonal nature of 
GBM.  The results showed distinct populations of the different subtypes are 
formed within a single spheroid that appear to arrange in a way most beneficial for 
tumour survival.  The presence of nutrient gradients, hypoxia and a necrotic core, 
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as well as an increased resistance to chemotherapy, suggests that spheroids are 
a better model of GBM tumours than using 2D monolayer cell lines.  However, it is 
unlikely the findings can be applied in vivo.  There are a number of other factors 
that influence the in vivo situation, for example drug delivery is different, rather 
having to pass through blood vessel walls to reach the tumour site.  Cooper et al., 
2012, suggested that the microenvironment is related to the specific gene 
expression patterns of the subtypes, which would not be comparable in spheroids 
in vitro.  The use of engineered cell lines to represent the subtypes also questions 
the applicability of the results.  This highlights the importance of recently 
developed mouse models of GBM, which have been engineered to develop the 
same genetic aberrations and allow the study of their relevance to gliomagenesis 
(Huse and Holland, 2009).  Thus, although spheroids are a simplified model of 
GBM, their use is still an important step in model design, bridging the gap between 
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